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Abstract 
 
Highly active antiretroviral therapy has successfully limited HIV-1 disease 
progression to AIDS, but is consistently compromised by the emergence and 
transmission of HIV-1 drug resistant strains. As a result, a continued search for novel 
anti-HIV-1 agents with improved pharmacological profiles has become fundamental. 
Chrysotherapy has been in use since the early 1920s in treatment of rheumatoid 
arthritis, and has since been investigated for various ailments including HIV/AIDS. 
This study evaluated 45 synthetic gold compounds for drug like properties using 
theoretical and experimental techniques with the aim of generating sufficient data to 
considerably aid the rational design of new anti-HIV agents.  Theoretical techniques 
applied included the Osiris Property Explorer and the Lipinski’s Rule of Five which 
assessed drug-likeness and bioavailability respectively. In vitro studies included 
aqueous solubility assays, cytotoxicity (PM1 cell lines and PBMCs) assays, antiviral 
assays in PBMCs, direct enzyme (RT and IN) inhibition, and the effect of serum 
protein binding and biological stability on antiviral efficacy. An overall low drug-
likeness score and an intermediate bioavailability were predicted by the Osiris 
Molecular Property Explorer. Low drug-likeness was suggested to be due to a high 
frequency of foreign fragments in the synthetic gold compounds, while their high 
molecular weight reduced bioavailability. In general gold compounds exhibited 
cytotoxicity properties and moderate aqueous solubility in vitro. Overall, the 45 
synthetic gold compounds did not show activity against HIV-1 replication in vitro. 
Seven compounds (AB05-AB11) exhibited direct HIV-1 RT inhibition, and 
compounds AB39 and AB04 demonstrated moderate direct HIV-1 IN inhibition, but 
this activity was abrogated in PBMC inhibition assays. Serum binding, compound 
stability and cytotoxicity were all implicated in the lack of HIV-1 inhibition in 
PBMCs. To this end, data obtained was sufficient to aid in the future rational design 
of second generation HIV RT and IN inhibitors with acceptable pharmacological 
properties. 
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CHAPTER 1 
INTRODUCTION 
 
 
1.1. Introduction to HIV and AIDS 
 
1.1.1.The history of HIV 
 
Acquired Immunodeficiency Syndrome (AIDS) was first identified in homosexual 
patients and described as an immune deficiency state associated with multiple 
microbial infections (Gottlieb et al., 1981). The viral agent associated with AIDS was 
isolated in 1983 from a lymph node of a homosexual patient with multiple 
lymphadenopathies, and was named Lymphadenopathy Associated Virus (LAV; 
Barre-Sinoussi et al., 1983). The name LAV was later changed to Human T-
Lymphotropic Virus Type (HTLV)-III due to the viral agent’s genomic similarities 
with HTLV-I (Gallo et al., 1984). HTLV-III was subsequently reported to be the 
causative agent of AIDS (Gallo et al., 1984 and Popovic et al., 1984). In 1986 the 
causative agent of AIDS was renamed Human Immunodeficiency Virus type 1 (HIV-
1) with relation to the immune depletion condition it causes (Coffin et al., 1986). In 
the same year, HIV-2 was isolated from West African commercial sex workers (Marx, 
1986). 
 
Until recently the only known historical HIV-1 sample was ZR59; a tissue sample 
obtained in 1959 from a Bantu male in Kinshasa, Democratic Republic of Congo 
(DRC) then Léopoldville (Zhu et al., 1998). The HIV-1 from ZR59 was later found to 
be closely related to a simian immunodeficiency virus (SIV) strain that originates in 
chimpanzees of the subspecies Pan Troglodytes troglodytes (Keele et al., 2006). 
Another HIV-1 sample (DR60) obtained from a female in Léopoldville was recently 
recovered. DR60 was a lymph node biopsy taken in 1960 and was since preserved in 
paraffin wax (Worobey et al., 2008). Genetic variations in the order of 12% 
introduced by mutations, between HIV-1 recovered from DRC60 and ZR59, 
suggested the presence of HIV-1 in humans for a significant period before 1960 
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(Worobey et al., 2008). An earlier report by Korber et al., (2000) compared the 
genetic make-up of modern HIV-1 to that from ZR59. It was estimated that HIV-1 
was present in humans between 1915 and 1941, with an optimum estimate for a 
common ancestor of the main HIV-1 group to be 1931 (Korber et al., 2000). 
 
1.1.2.The epidemiology of HIV  
 
HIV-1/AIDS has since its discovery become a global public health predicament of 
pandemic magnitude (Fauci, 2006). Recent studies have estimated that by the end of 
2009, approximately 33.3 million (range: 31.4 million - 35.3 million) people were 
living with HIV-1 worldwide (UNAIDS, 2010). Sub-Saharan Africa was reported as 
the region most affected by the HIV-1 pandemic (UNAIDS, 2010). The region 
accounts for approximately 67% of the total number of people living with HIV-1 and 
75% of all AIDS-related mortalities (UNAIDS, 2010). In the same study South Africa 
was reported to be the country with the highest global estimates of people living with 
HIV-1 infection (UNAIDS, 2010). An estimated 5.7 million people are reported to be 
living with HIV-1 in South Africa with over 250,000 AIDS related mortalities in 2008 
alone (Department of Health, 2010). The South African national HIV-1 survey 
estimates the national prevalence of HIV-1 at 10-11%. Approximately 10.9% of all 
South Africans over two years of age were reported to be living with HIV-1 in 2008, 
with adults having the highest rates of HIV-1 at 16.9% (Department of Health, 2010). 
Children between the ages 2-14 have an estimated HIV-1 prevalence of 
approximately 2.5%, and HIV-1 prevalence among the youth (ages 14-24) was 
estimated at approximately 8.7 % in South Africa (Department of Health, 2010). The 
HIV-1 prevalence is highest among the African population at 13.6%. The coloured, 
white and Indian population’s HIV-1 prevalence rates are estimated at 1.7%, 0.3% 
and 0.3% respectively (Department of Health, 2010). The prevalence of HIV-1 
infection among women attending antenatal clinics across South Africa has been 
estimated at approximately 28% (Department of Health, 2010); with Kwazulu-Natal, 
Mpumalanga and the Free State being provinces with the highest recorded HIV-1 
prevalence rates at 37.4%, 32% and 33%, respectively (Department of Health, 2010). 
The Western Cape and the Northern Cape are provinces with the lowest HIV-1 
prevalence rates of 6.1% and 12.6%, respectively, with heterosexual transmission 
being the main route of transmission (Department of Health, 2010). Other HIV-1 
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transmission modes include homosexual transmission, intravenous drug use and 
mother to child transmission (Global HIV Prevention Working Group, 2007).  
 
1.1.3. Nomenclature and phylogeny of HIV 
 
The HI virus is classified as a member of the family Retroviridae, subfamily 
Orthoretrovirinae and genus lentivirus   (ICTVdB – The Universal virus database, 
version 4. http://www.ncbi.nlm.nih.gov/ICTVdb/ICTVdB/ accessed 08-09-2010). 
There are 2 distinct types of human HIV, namely HIV-1 and HIV-2. These viruses are 
distinguished on the basis of their genome organizations and evolutionary relations to 
primate lentiviruses as illustrated in Figure 1.1 Three transmissions of SIVcpz from 
the central African chimpanzee subspecies (Pantroglodytes troglodytes and 
schweinfurthii) gave rise to HIV-1 groups M, N and O and the other SIVsmm gave 
rise to HIV-2 groups A and H (Chen et al., 1997; Gao et al., 1999; Santiago et al., 
2002, Worobey et al., 2007). 
 
HIV-2 consists of 5 distinct phylogenetic lineages designated as groups A, B, C, F 
and G, and one circulating recombinant form (CRF); 
(http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html accessed 19-07-
2010). HIV-1 was classified into 3 groups M, N and O with each lineage representing 
a separate transmission event in chimpanzees in central Africa (McCutchan, 2006). In 
2009, a new HIV-1 sequence was isolated from a Cameroonian woman who was 
residing in France; the virus was designated HIV-1 group P and exhibited close 
relations to SIV discovered in gorillas (Plantier et al., 2009). The HIV-1 group M 
which is responsible for most of the global HIV-1 epidemic consists of nine subtypes 
designated A-D, F-H, J, and K, 48 CRFs, and numerous unique recombinant forms 
(URFs) (Robertson et al., 2000; Hemelaar et al., 2006; McCutchan, 2006 and 
http://www.hiv.lanl.gov accessed 19-07-2010). Formation of new lineages occurs as a 
result of the HIV-1’s high mutation rate. The sequence mutations are introduced 
during reverse transcription since the viral reverse trancriptase (RT) enzyme lacks 
proof reading ability and as a result of viral recombination among quasispecies 
(Coffin, 1986; Hahn et al., 1986; Richetti et al., 1990; Zhang et al., 1994; Robertson 
et al., 1995; Ho, 1997 and Levy et al., 2004). These evolutionary processes had 
produced the well-Characterised CRFs such as CRF02_AG, CRF08_BC, 
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CRF15_01B, CRF09_cpx, CRF01_AE and CRF04_cpx within HIV-1 group M 
(McCutchan, 2006). CRFs are numbered sequentially as they become known and 
designated according to HIV-1 subtypes recombined. For instance, CRF02_AG 
represents a subtype A and a subtype G recombinant (Howard and Rasheed, 2006). In 
a situation where recombination has occurred between more than two subtypes the 
CRF is labelled with a designation cpx (complex). For instance, CRF04_cpx 
represents a recombinant form comprised of four subtypes, namely A, G, H, K and 
some unclassified regions (Paraskevis et al., 2001). To date, 48 HIV-1 and 1 HIV-2 
CRF has been described (http://www.hiv.lanl.gov accessed 19-07-2010). Numerous 
URFs have been identified, and represent a large and heterogeneous group of HIV-1 
strains (McCutchan, 2006). They are a reflection of a mixture of subtypes in a 
population where they are found and some may be generated within an individual 
with dual infection of HIV-1 (infection by two or more distinct viruses; Gerhardt et 
al., 2005; McCutchan et al., 2005). 
 
Figure 1.1: Lentivirus phylogenetic tree illustrating maximum likelihood relations between HIV-1, 
HIV-2 and SIV partial sequences.  This Figure was obtained from Worobey, 2007. 
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1.1.4. Geographical distribution of HIV 
 
HIV lineages are to a large degree associated with geographical distribution. HIV-2 
infections are prevalent in West Africa. HIV-2 has a prevalence of more than 1% in 
West African nations such as Cape Verde, Ivory Coast, Gambia, Guinea-Bissau, Mali, 
Mauritania, Nigeria and Sierra Leone (Centres for Disease Control and Prevention: 
http://www.cdc.gov/hiv/resources/factsheets/hiv2.htm accessed 26-08-2010). Other 
West African countries that report an incidence of HIV-2 infection are Benin, Burkina 
Faso, Ghana, Guinea, Liberia, Niger, São Tomé, Senegal and Togo. Southern African 
states such as Angola and Mozambique have also reported an over 1% prevalence rate 
of HIV-2 infection (Centers for Disease Control and Prevention, Last Reviewed: 
August 11, 2010). HIV-2 is therefore considered to be less transmissible and less 
pathogenic than HIV-1 (McCutchan, 2006). HIV-1 group O is most prevalent in 
Cameroon and neighbouring West African countries, where it accounts for 
approximately 1 to 5% of HIV-1 positive samples (Peeters et al., 1997). Similarly, 
HIV-1 group N viruses have been identified in a few individuals from Cameroon 
(Simon et al., 1998; Ayouba et al., 2000 and Yamaguchi et al., 2006). HIV-1 group M 
viruses are responsible for the main pandemic worldwide (Human Retroviruses and 
AIDS 1999: A Compilation and Analysis of Nucleic Acid and Amino Acid 
Sequences). Only six of all HIV-1 group M strains dominate the HIV-1 pandemic, 
namely; subtypes A, B, C, D, CRF01_AE and CRF02_AG (McCutchan, 2006). HIV-
1 subtype K has been reported in the Democratic Republic of Congo and Cameroon 
(Hemelaar et al., 2006). HIV-1 subtypes F, G, H and J have been reported in South 
America and Western Europe; Africa and Central Europe; Central Africa; and the 
Caribbean, North, Central and West Africa (http://www.avert.org/hiv-types.htm 
accessed 20-49-2010). The HIV-1 group M subtypes also vary in geographical 
distribution. For instance, subtype A is prevalent in West Africa and the Republics of 
the Soviet Union (Robertson et al., 1995 and McCutchan, 2006). Subtype B is 
prevalent globally but dominates the epidemics in South and North America, Western 
Europe and Australia (Bobkov et al., 2004). Subtype C accounts for more than 50% 
of all infections worldwide but is predominant in Southern Africa, East Africa and 
India (Buonaguro et al., 2007). Subtype D predominantly circulates in East Africa 
(McCutchan, 2006). Similarly, CRF01_AE is the major strain throughout Southeast 
Asia and CRF02_AG dominates in West Africa (McCutchan, 2006). Related CRFs 
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such as CRF07_BC and CRF08_BC have been identified in China (McCutchan et al., 
2002). CRF02_AG and the CRF09_cpx are prevalent in West Africa (McCutchan et 
al., 2004). Interestingly, approximately 30% of strains in East Africa are URF’s 
(Dowling et al., 2002; Harris et al., 2002; Arroyo et al., 2004 and Arroyo et al., 
2005); more URF’s are also prevalent in the epidemics of West Central Africa and 
parts of South America (Carr et al., 2001a; Carr et al., 2001b; Thompson et al., 2004b 
and Sierra et al., 2005). 
 
 1.1.5. The HIV virion 
 
A mature HIV virion is spherical to pleomorphic in shape with a diameter of 90-
130nm (Gallo et al., 1984; Gonda et al., 1985 and Lytle et al., 1992).  HIV is an 
enveloped virus as shown in Figure 1.2. The envelope of the virion is a lipid bilayer 
derived from the host cell plasma membrane (Arthur et al., 1992), within which the 
viral envelope glycoproteins are embedded. The envelope is comprised of 72 
envelope glycoprotein projections which are 9-10nm in length and 14-15nm in 
diameter formed from a precursor molecule gp160 (Gelderblom, 1991 and 
Hallenberger et al., 1997). Each spike consists of three (trimeric) surface gp120 
glycoproteins that are noncovalently bound to three transmembrane gp41 molecules 
(Earl et al., 1990 and Weiss et al., 1990). 
 
 
Figure 1.2: Schematic diagram of a mature virion. This Figure was taken from: 
http://health.howstuffworks.com/diseases-conditions/infectious/aids2.htm accessed 07-09-2011 
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HIV is a positive sense single stranded RNA virus with a genome representing 
approximately 2% of the overall viral mass. The genome is a monomer of 
approximately 9200 nucleotides that form three main genes in the order: 5’-gag-pol-
env-3’ as illustrated in Figure 1.3. The gag and the env genes encode structural 
proteins; the pol gene encodes the enzymes RT, RNaseH, integrase and protease 
(Gelderblom, 1991). HIV-1 consists of other genes whose functions are regulatory 
(tat and rev) and accessory (vpr, vif, vpu and nef) to the replication process (reviewed 
in Table 1.1). The HIV-2 genome is similar, but contains vpx instead of vpu. When 
integrated, the viral genome is flanked by two identical long terminal repeats (LTRs). 
 
Figure 1.3: The complete HIV-1 genome.  This Figure was taken from Jacque et al., 2002 and depicts 
the three main genes gag, pol and env and regulatory and accessory genes essential for HIV-1 
replication. 
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Table 1.1: The size and functions of HIV-1 regulatory, accessory and structural 
proteins. 
Gene Products Size (kDa) Function 
Regulatory Gene Products 
Tat 14 Regulates viral gene expression [a] 
Rev 18 Nuclear transport of viral RNA, stability and 
utilization factor [b] 
Accessory Gene Products 
Nef 25-27 Down regulates cell surface CD4 and MHC-I 
molecules[c] 
Augments virus infectivity[c] 
Modulates signalling pathways of cells[c] 
Vpr 15  Nuclear localization of the pre-integration complex 
(PIC), inhibits cell division, arrest cells in G2/M[d] 
Vif 23 Promotes virus infectivity,[e] inhibits APOBEC3G 
Vpu 17 Induces CD4 receptor degradation in the 
endoplasmic reticulum, thus enhance budding[f] 
Structural Gene Products 
   Gag 
MA 17 Membrane anchoring, env interaction and nuclear 
transport of viral core[g] 
CA 24  Core capsid[g] 
NC 7  
6  
Nucleocapsid, binds RNA 
Binds Vpr[g] 
   Pol 
Protease (Pr) 10~12 Cleavage of Gag-pol polyprotein precursor and 
maturation[g] 
Reverse 
transcriptase (RT) 
~117 RNA-dependent and DNA-dependent polymerase 
activities[g] 
RNaseH activity catalyses the cleavage of DNA 
bound RNA via a hydrolytic mechanism[g] 
Integrase (IN) 32 mediates the insertion of the HIV-1 proviral cDNA 
into the genomic DNA[g] 
   Env 
Gp160 160 Gp120 and gp41 precursor[h] 
Gp120 120 CD4 and co-receptor binding[h] 
gp41 41 Membrane Fusion[h] 
 [a] Seelamgari et al., 2004. [b]  Glushakova et al., 2001., Shaheduzzaman et al., 2002., Stoddart et al., 
2003  [c] Zhang et al., 2001., Sherman et al., 2002., Yao et al., 2002., Tungaturthi et al., 2003., [d] 
Montal, 2003. [e] Sheehy et al, 2003 [f] Fischer et al., 1987., Strebel et al., 1987. [g] Kuiken et al., 2008 [h] 
Capon and Ward, 1991., Bernstein et al., 1995. 
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 1.1.6. Life cycle of HIV 
 
The typical HIV-1 life cycle comprises several phases i.e. attachment, fusion, reverse 
transcription, integration, transcription and translation, viral assembly, budding and 
maturation as shown in Figure 1.4 below.  
 
 
Figure 1.4: A schematic illustration of the typical HIV-1 life cycle. This Figure was taken from 
Subramani et al., 2005. 
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 1.1.6.1. HIV entry and tropism 
 
The life cycle of HIV-1 begins with viral entry into a host cell, as shown in Figure 
1.4. Viral entry into a CD4 positive T-lymphocyte is a complex process that consists 
of a series of coordinated events that are mediated by the gp120 glycoprotein. The 
gp120 binds to CD4 receptors (attachment) on the surface of the target cell (Samson 
et al., 1996). This interaction introduces conformational changes in the trimeric gp120 
molecule, which then leads to co-receptor binding (either CCR5 or CXCR4). The T-
tropic (X4) viral strains use the CXCR4 co-receptors and the M-tropic (R5) viral 
strains use the CCR5 co-receptor for cell entry (Manzoni et al., 1990; Lambert and 
Feltz, 1995; Nakai et al., 1996; Berger, 1997 and Berkowitz et al., 1998). Dual 
tropism for the CXCR4 and CCR5 co-receptor has been reported and these viral 
strains are classified as R5X4 (Berger et al., 1998). The M-tropic viral strains are 
predominant in the early asymptomatic phases of HIV-1 infection and thus CCR5 is 
regarded as the primary co-receptor for initial HIV-1 infection (Chavis et al., 1994; 
Chavis et al., 1995; Nakai et al., 1996 and Samson et al., 1996). The principal 
genotypic determinant of co-receptor usage is the V3 variable loop within the gp120 
molecule (Hwang et al., 1991; Shioda et al., 1991; Carrillo et al., 1996 and Soulie et 
al., 2008). In addition, modifications in the V1 and V2 variable loops of gp120 have 
been reported to also introduce variations in HIV-1 co-receptor usage (Groenink et 
al., Groenink et al., 1992; Groenink et al., 1993; Masciotra et al., 1993 and Chesebro 
et al., 1996).  
 
Co-receptor binding further induces exposure of the gp41 ectodomain (Myszka et al., 
2000 and Salzzwedel & Berger, 2000). The gp41 consists of a cytoplasmic and 
transmembrane domain in addition to the ectodomain. The ectodomain is made up of 
four major functional regions; the Tryptophan-rich pretransmembrane domain (PTD), 
the C-terminal heptad repeat (CHR), the N-terminal heptad repeat (NHR) and a 
stretch of 15 hydrophobic residues located in the fusion peptide (FP) (Rabenstein et 
al., 1995 and Lev et al., 2007). The gp41 adopts a trimeric extended pre-hairpin 
intermediate (PHI) conformation that allows insertion of the FP into the host cell 
membrane (Jones et al., 1998 and Melikyan et al., 2006). The PHI conformation is 
short-lived (±30 minutes). The PHI later collapses into a low-energy conformation of 
a six helix bundle (SHB) (Furuta et al., 1998 and Munoz-Barroso et al., 1998).  The 
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SHB was believed to pull together the viral and cell membranes, but it has been 
shown that fusion pores on cell membranes form before the complete folding of the 
SHB (Markosyan et al., 2003). Therefore the actual mechanism of fusion is yet to be 
elucidated (Lev et al., 2007). Fusion of the viral membrane with the host cell plasma 
membrane induces penetration of the viral p24 core into the host cell cytoplasm. 
 
1.1.6.2. Reverse transcription 
 
HIV-1 entry is followed by a poorly understood process of uncoating which modifies 
the viral core such that reverse transcription can occur (Sarafianos et al., 2009). 
Reverse transcription is a process catalysed by the RT enzyme; a heterodimer 
consisting of subunits p66 and p51 (DiMarzo-Veronese et al., 1986 and Lightfoote et 
al., 1986). The RT enzyme has three catalytic functions: the RNA dependent DNA 
polymerization, RNaseH activity and DNA dependent DNA polymerization (Goff, 
1990). Both the p66 and the p51 exhibit polymerase activity; which is largely 
dependent on the N-terminal portions of both subunits (Hansen et al., 1988); while the 
RNaseH activity is only associated with the C-terminal portion of the p66 subunit 
(Hansen et al., 1988). 
 
The initiation of reverse transcription occurs at a site in the viral genome known as 
the primer binding site which consists of eighteen nucleotides complementary to the 
3’-terminal end of cellular transfer RNA (tRNA)Lys. The partially unwound tRNALys 
initiates reverse transcription by annealing to the 5’ region of the primer binding site 
(Novel, 1994). The viral RT extends the primer tRNA by synthesis of a 
complementary DNA (cDNA; minus-strand strong-stop DNA) from the 3’OH of the 
primer to the 5’ terminus (van Wamel et al., 1998). Synthesis of the cDNA occurs 
concurrently with the degradation of the RNA template by RNaseH resulting in a 
single stranded cDNA (Gopalakrishnan et al., 1992 and Jacobo-Molina et al., 1993). 
Thereafter, RT generates a polypurine oligonucleotide at the 5’ end of the cDNA; 
which is subsequently copied by extension of the 3’ end of the primer into a double 
stranded cDNA (Jiang et al., 1993 and Nouvel, 1994). The methylated adenosine 
residues and the secondary structure on the primer binding site act as stop signals 
during synthesis of cDNA (Jiang et al., 1993 and Nouvel, 1994). 
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However, the HIV-1 RT is error prone, and introduces mutations into the viral 
genome with each replication cycle, resulting in numerous quasispecies within an 
infected individual. 
 
1.1.6.3. Proviral DNA integration 
 
Subsequent to reverse transcription the cDNA is prepared for insertion into the host 
genome. This process is catalysed by the 288-amino acid viral integrase enzyme 
(32kDa). The integrase enzyme consists of 3 independent domains. The N-terminal 
domain (amino acids 1-49) that carries a HisX3
-7HisX23-32CysX2Cys (HHCC) motif 
analogous to a zinc finger, and effectively binds Zn2+ (Zheng et al., 1996). The second 
domain is the central/catalytic domain (amino acids 50-212) composed of residues 50-
212, an RNaseH type fold, and the active site, which is comprised of two Asp residues 
and one Glu, in a typical DDE motif essential for catalytic activity and viral DNA 
binding (Engelman et al., 1992; Kulkosky et al., 1992; van Gent et al., 1993 and 
Johnson et al., 2006). The C-terminal domain (amino acids 213-288) is mainly 
involved in stabilizing the pre-integration complex (PIC) by non-specific binding to 
viral cDNA (Wang et al., 2001 and Chen et al., 2000).  
 
Viral DNA integration is a two step process. The first step involves indolytic cleavage 
of the viral cDNA in the cytoplasm to generate dinucleotide cytosine-adenine (CA) 
overhangs in a process referred to as 3’ processing.  The 3’ processing step requires a 
fully functional integrase, the integrity of the last 10-20 base pairs at both ends of the 
viral cDNA and the presence of specific metallic cationic co-factors such as Zn2+ and 
Mg2+ (Lee et al., 1997 and Pommier et al., 2005).  
 
After 3’-processing, integrase remains bound to the PIC which consists of various 
viral and cellular proteins in addition to the viral cDNA. The properties of the viral 
PIC have been attributed mainly to three viral proteins: matrix (MA), nucleocapsid 
(NC) and Vpr which contribute to the complex nuclear import process of the PIC 
(Bukrinsky et al., 1992). Cellular factors such as Lens Epithelium-Derived Growth 
Factor/p75 (LEDGF/p75) protein, the DNA flap structure of the viral cDNA, 
importin-α and importin-β have also been implicated in promoting the translocation of 
the PIC into nuclei of virally infected cells (Zennou et al., 2000; Maertens et al., 2003 
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and Llano et al., 2004). Despite extensive research into the area, the mechanism of 
nuclear import remains unclear (Sherman et al., 2002 and Levin et al., 2009).  
 
Once in the nucleus, the HIV-1 integrase enzyme catalyses the second step, the strand 
transfer reaction (Chiu et al., 2004). The strand transfer reaction involves the ligation 
of the 3’-OH cDNA ends generated from 3’-processing, onto the 5’-DNA phosphates 
of the host chromosome (reviewed by Pommier et al., 2005). This process involves a 
concerted joining of both ends of the viral cDNA and the host genomes’ five base 
stagger which is a result of chromosomal DNA cleavage across the groove (reviewed 
by Pommier et al., 2005; Yoder et al., 2000). The final step requires trimming of the 
last two nucleotides at the 5’ ends of the proviral DNA and extension from the 3’-OH 
chromosomal DNA (Yoder et al., 2000). HIV-1 integration into the host chromosome 
is an reversible process, and there does not appear to be any specificity with respect to 
integration sites, although active genes are favoured (Yoder et al., 2000, Chiu et al., 
2004, reviewed by Pommier et al., 2005).    
 
1.1.6.4. Transcription and translation  
 
The replication phase includes the transcription of the proviral DNA into RNA 
molecules and their translation into polypeptide precursors (Freed, 2002). The RNA 
transcription process is initiated by RNA polymerase binding to the proviral DNA and 
increased levels of the Tat protein that elevates the basal transcriptional activity of the 
HIV-1 LTR (Dayton et al., 1986 and Fischer et al., 1986). Tat binds the RNA 
transactivation response region (TAR) which leads to increased levels of the human 
positive-transcriptional elongation factor P-TEF-b (Berkhout et al., 1989 and Freed, 
2002). The P-TEF-b phosphorylates the C-terminal domain of RNA pol II and this 
stimulates radical transcription (Freed, 2002). Transcription generates a variety of 
viral RNAs (up to 30 RNA species) that include unspliced RNAs, partially spliced 
mRNAs (5kb) and small (1.7 to 2.0 kb) multiply spliced mRNAs. The partially 
spliced mRNAs are translated into Gag and Gag-Pol polyprotein precursors. The 
partially spliced mRNAs encode the Env, Vif, Vpu and Vpr proteins. The multiply 
spliced mRNAs are translated into Tat, Nef and Rev (Purcell et al., 1993 and Freed, 
2002). Some proteins undergo post-translational modifications, such as glycosylation 
(Env) and myristolation (Nef). 
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1.1.6.5. Assembly, budding and maturation 
 
HIV-1 maturation requires cleavage of the Gag-Pol polyproteins by the aspartyl 
protease enzyme to allow maturation of nascent viral particles. (Kohl et al., 1988). 
HIV-1 protease exists as a homodimer with two identical subunits; the active site of 
the enzyme lies between the subunits.  Cleavage of the polyprotein produces four 
structural proteins which are p24, p17, p7 and p6, whose function includes RNA 
packaging (Henderson et al., 1992). HIV-1 protease cleavage occurs at sites 
consisting of phenyl-alanine-proline bonds and tyrosine-proline bonds uncommon on 
mammalian polypeptides (Debouck et al., 1992). Proteolytic cleavage introduces 
morphologic changes in structural proteins followed by assembly of the virion. Viral 
structural and enzymatic proteins travel to the host plasma membrane where immature 
virions assemble in cholesterol rich lipid rafts. The Gag p6 recruits components of 
multivesicular bodies, which facilitate the release of progeny virions from the cell 
(Overton et al., 1990). As new immature virions emerge from the host cell, the host’s 
lipid membranes remain to form the envelope, within which the viral gp120 and the 
gp41 heterotrimers are embedded (Overton et al., 1990). The protease is packaged 
into virions which allows for continued cleavage of the Gag polyprotein to occur 
simultaneously with the budding process (Overton et al., 1990). Complete processing 
of the Gag and Gag-Pol in the immature virion yields a mature infectious HIV-1 
particle capable of initiating another round of infection.  
 
 
1.1.6.6. Viral replication   
 
The process of cell infection starts with the attachment of free virions to host cells 
(Anderson, 2010) as outlined in the life cycle above. Cell infection can also occur in 
varying mechanisms i.e.  cell-to-cell transmission (Mothes et al., 2010), mitosis of an 
infected cell generating two viral-producing progeny cells (Philips, 1994) and through 
phagocytosis (Noursadeghi et al., 2006).  
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1.2. HIV-1 treatment 
 
The discovery of HIV-1 as the causative agent of AIDS in the early 1980s has since 
led to considerable success in the development of anti-HIV drugs. To date, there have 
been more drugs approved for the treatment of HIV-1 infection than any other viral 
infection (as reviewed in Mehellou and De Clercq, 2009). HIV drugs are currently 
subdivided into four drug classes, RT inhibitors (i.e. nucleoside inhibitors/NRTIs, 
nucleotide inhibitors/NtRTIs and non- nucleoside inhibitors/NNRTIs), protease 
inhibitors (PIs), entry inhibitors (i.e. a fusion inhibitor/FI and a co-receptor antagonist 
(CRA) and integrase inhibitors (INIs) as summarized in Table 1.2. 
 
1.2.1. RT inhibitors/RTIs 
 
The NRTIs and NtRTIs exhibit anti-HIV RT activity post phosphorylation by cellular 
kinases into triphosphate/diphosphate metabolites (Balzarrini, 1994 and Hao et al., 
1990). The active moieties interact with DNA polymerases allowing incorporation of 
the nucleoside/tide analogues into a growing DNA chain. Incorporation of RTIs’ into 
a growing DNA chain leads to chain termination due to the active moiety’s lack of a 
3’-hydroxyl group which prevents further assimilation of nucleotides (Mehellou and 
De Clercq, 2009).  
 
By contrast, the NNRTIs exhibit anti-HIV RT activity through non-competitive 
binding to an allosteric site located a short distance (~15 Å) from the catalytic site (De 
Clerq et al., 2004 and Pauwels, 2004).  
 
1.2.2. Protease inhibitors/PIs 
 
PIs inhibit the proteolytic cleavage of HIV-1 Gag and Gag-Pol polyproteins and this 
prevents the maturation of virions. Some PI’s are transition-state analogues that bind 
competitively to the active site of the homodimeric enzyme located between 
monomers, therefore preventing substrate binding (Bannwarth et al., 2007). Other 
PI’s, such as interface peptides, interact with the N- and the C- terminal ends of the 
dimerized monomers which leads to dissociation of the dimer (Bannwarth and 
Reboud-Ravaux, 2007). 
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1.2.3. Entry inhibitors 
 
The approved FI (enfuvirtide) is homologous to a segment on the HR2 region (amino 
acids 643-678 of the HXB2 sequence) of the gp41. The binding of FI locks the gp41 
in a transition state (Wild et al., 1993; Wild et al., 1994; Chen et al., 2002; Kilby et 
al., 2003; LaBonte et al., 2003 and Moyle, 2003) and therefore prevents formation of 
the six-helix bundle hairpin structure necessary for fusion.  
 
The CCR5 antagonist Maraviroc acts by binding directly to the transmembrane CCR5 
co-receptor. Maraviroc binds within the 2, 3, 6 and 7 helix near the CCR5 
extracellular surface (Dragic et al., 2000 and Briz et al., 2006), thereby preventing 
gp120 binding to the co-receptor.  
 
1.2.4. Integrase inhibitors/INs 
 
The recently FDA approved IN inhibitor Raltegravir (Isentress; Merck and co) is a 
structural analogue of the di-keto acid class of compounds (Hazuda et al., 2000). 
Raltegravir is a known inhibitor of the strand transfer reaction in HIV-1 integration 
(Hazuda et al., 2000; Zahm et al., 2008) with a concentration required to reduce 
replication by 50% (IC50) of approximately 10nM (Merck & Co. Inc. IsentressTM, 
Raltegravir, 2007) and an IC95 of 33nM in 50% human serum albumin (Iwato et al., 
2008). 
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Table 1.2: Classification of currently available anti-HIV drugs. Information was 
obtained from http://www.thebody.com/content/treat/art5295.html accessed 07-09-2011 
RTIs  Trade name  Company 
Azidothymidine Retrovir/Retrovis GlaxoSmithKline 
Zalcitabine Hivid Hoffman LaRoche 
Dideoxyinosine Videx/Videx EC Bristol Myers Squibb Co 
Abacavir Ziagen GlaxoSmithKline 
Racivir Coviracil Pharmasset 
Lamivudine Zeffix/Heptovir/Epivir/ GlaxoSmithKline 
Tenofovir Viread Gilead Sciences 
Efavirenz Sustiva/Stocrin Bristol Myers Squibb Co 
Etravirine Intelence Tibotec Pharmaceuticals 
Nevirapine Viramune Boehringer Ingelheim 
Delavirdine Rescriptor Pfizer 
Stavudine  d4T/Zerit Bristol-Myers Squibb 
Emtricitabine  Emtriva Gilead Sciences 
PIs    
Saquinavir Invirase/Fortovase Roche 
Ritonavir Norvir Abbott Laboratories 
Darunavir Prezista Tibotec 
Indinavir Crixivan Merck 
Tipranavir Aptivus Boehringer Ingelheim 
Fosamprenavir Lexiva/Telzir GlaxoSmithKline 
Nelfinavir Viracept Pfizer/Hoffman LaRoche 
Atazanavir Reyataz  Bristol Myers Squibb Co 
Lopinavir Kaletra/Aluvia Abbott Laboratories 
Amprenavir Agenerase GlaxoSmithKline 
FIs    
Enfuvirtide Fuzeon Roche 
CRA   
Maraviroc Selzentry/ Celsentri Pfizer 
INIs    
Raltegravir Isentress Merck 
 
 
1.2.5. Anti-HIV drugs in development 
 
There are numerous potential drug candidates with anti-HIV activity undergoing 
phases II and III human clinical trials as shown in Table 1.3. Some of these anti-HIV 
drug candidates act through previously established inhibition mechanisms. However 
they represent the next generation of anti-HIV drugs with better resistance and 
toxicity profiles. Other exciting elements from Table 1.3 include the fact that half of 
 Chapter 1 
 18 
these candidate anti-HIV drugs belong to relatively new classes such as the entry 
inhbitors. Agents belonging to drug classes with novel mechanisms of action have 
enriched existing anti-HIV therapy and will contribute considerably towards delaying 
the onset of antiretroviral drug resistance if successful (Mehellou and De Clercq, 
2010). 
 
Table 1.3: Anti-HIV drugs currently undergoing human clinical trials (Phase II and 
Phase III).  This information was obtained from a review study by Mehellou and De 
Clercq, 2010. 
Drug Class Developer Phase 
Apricitabine NRTIs Avexa III 
Amdoxovir NRTIs RFS Pharm II 
Elvucitabine NRTIs Achillion Pharmaceuticals II 
Racivir NRTIs Pharmasset II 
BILR 355 BS NNRTIs Boehringer Ingelheim II 
(+)-calanolide A NNRTIs Sarawak MediChem Pharmaceutics II 
IDX899 NNRTIs Idenix Pharma I/II 
MIV-150 NNRTIs Medivir, Chiron II 
RDEA806 NNRTIs Ardea II 
Rilpivirine NNRTIs Tibotec IIb 
AK-602 CRAs Kumamoto University III 
AMD070 CRAs AnorMed II 
HGS004 CRAs Human Genome Sciences II 
Ibalizumab (TNX-355) CRAs TailMed Biologics II 
PF-232798 CRAs Pfizer II 
VCH-286 CRAs ViroChem Pharm II 
Vicriviroc CRAs Schering Plough III 
PRO 140 FIs Progenics II 
SP01A EI Samaritan Pharmaceuticals III 
Elvitegravir INIs Gilead Sciences III 
 
 
1.2.6. Highly active antiretroviral therapy (HAART) 
 
HIV/AIDS treatment guidelines stress the use of highly active antiretroviral therapy 
(HAART). HAART was introduced following a rational strategy to delay the 
emergence of HIV-1 drug resistance through potent virus suppression (reviewed by 
Carpenter et al., 1997).  Combination therapy which consists of two or more drugs 
with varying mechanisms of action provided the required viral suppression to delay 
the emergence of viral drug resistance (Gupta et al., 2008; Mehellou and De Clercq, 
2009). Initial HAART regimens resulted in high pill intakes which led to decreased 
 Chapter 1 
 19 
compliance and adherence rates. The reduced adherence rates led to efforts to design 
single formulations of HAART by careful selection of regimens that demonstrated 
synergy as listed in Table 1.4 (Carpenter et al., 1997, Mehellou and De Clercq, 2010). 
 
Table 1.4: List of currently FDA-approved anti-HIV drug combinations. This table 
was adapted from a review study by Mehellou and De Clercq, 2010. 
Combination Components Manufacturer 
Combivir Zidovudine, Lamivudine GlaxoSmithKline 
Trizivir Abacavir, Lamivudine, Zidovudine GlaxoSmithKline 
Epzicom/Kinexa Abacavir, Lamivudine GlaxoSmithKline 
Truvada Tenofovir, Emtricitabine Gilead Sciences 
Atripla Tenofovir, Emtricitabine, Efavirenz Bristol Meyers Squibb, 
Gilead Sciences 
 
Marked and sustained reductions in HIV/AIDS related mortality and morbidity rates 
have been observed since the inception of HAART (Palella et al., 2002 and Mocroft 
et al., 2003). The use of HAART is associated with prolonged disease-free patient life 
and reductions in hospitalization rates due to potent viral suppression and CD4+ T-
cell repletion (Fleishman and Hellinger, 2003). The success of HAART has been 
reported numerous times. For instance, a multicentre study in twelve high-income 
countries has shown a decline of approximately 85% in mortality rates among people 
living with HIV in comparison to the uninfected population, following the 
introduction of HAART (Bhasaran et al., 2008). More evidence suggests that 
expansion of HAART programs into resource limited areas has reduced HIV/AIDS 
mortality rates considerably. For instance, a cohort study in Uganda demonstrated a 
95% reduction in HIV/AIDS mortality following introduction of HAART (Mermin et 
al., 2008). An antiretroviral (ARV) scale-up program in Malawi reduced mortality 
rates among adults by 35% (Jahn et al., 2008). ARV scale-up programs in Botswana 
show that approximately 79% of adult’s enrolled for treatment in the early stages of 
infection were still alive five years after initiation of therapy (Bussmann et al., 2008).  
 
South Africa is one country that has also recently began to experience the public 
health benefits that are associated with the implementation of the government ARV 
roll-out program which was initiated in April 2004. For example, the Western Cape 
Province, has since inception of the HAART programme seen its six month mortality 
rate among patients fall by half (12.7% - 6.6%) between 2001/2002 and the year 2005 
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(Boulle et al., 2008). The Umkhanyakude District in the Kwazulu-Natal Province, has 
seen mortality rates fall by 22% among woman aged 25-49 and 29% among men  
from the period 2002/2003 to 2004/2006 (Herbst et al., 2009). 
 
In South Africa, the antiretroviral therapy (ART) roll-out programme began slow but 
has since progressed from the 32895 HIV-1 patients in January 2005 to 871,914 HIV 
patients on ARVs in 2009 (Rehle et al., 2010). Although successful implementation 
seemed costly and socially complex (Benatar, 2004; Natrass, 2007); evidence 
suggests accomplishments would be determined by a better understanding of the wide 
social, geographical and cultural issues regarding HIV/AIDS (Murray, 2009). For 
instance, HIV/AIDS in South Africa is associated with racial and ethnic dimensions 
(De Vos and Baim-Lance, 2002; Gilbert and Walker, 2009).  
 
1.3. Antiretroviral drug resistance 
 
The use of combination therapy has proven remarkably effective in controlling the 
progression of the HIV epidemic, but the benefits are still compromised by the 
emergence of ARV drug resistant strains (Palella et al., 1998; Lederberger et al., 1999 
and DeGruttola et al., 2000). More than 200 mutations (clinical and in vitro) 
associated with ARV resistance to the four classes of drugs have been characterised 
and more than ninety of these are associated with HIV RT (Shafer et al., 2008).  
 
1.3.1. HIV RT ARV drug resistant strains 
  
ARV drug resistance mutations associated with NRTI’s include M184V, thymidine 
analogue mutations, mutations associated with non-thymidine analogue containing 
regimens, multi-nucleoside resistance mutations and several recently identified 
accessory mutations. NRTI’s mutations exceed fifty in number and NNRTI drug 
resistance mutations exceed forty (Shafer et al., 2008). Drug resistance to NRTIs may 
arise through the removal of the chain terminating residue; a kind of repair reaction 
involving pyrophosphorolysis developed by the mutant RT (De Clercq, 2002). 
Another NRTI resistance mechanism involves enhanced discrimination of the 
analogues in favour of authentic nucleotides by the mutant RT (Deval et al., 2002; 
2004). 
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NNRTI ARV drug resistance mutations include polymorphic and non-polymorphic 
accessory mutations.Polymorphisms are mutations that occur without selective drug 
pressure, and non-polymorphisms occur when virus is exposed to drug (Shafer et al., 
2007; Shafer et al., 2008). Almost all NNRTI resistance mutations are located within 
the binding site or adjacent to residues within the binding site thus preventing 
allosteric binding (Sarafianos et al., 2004 and Ren et al., 2008). 
 
1.3.2. HIV PI ARV drug resistant strains 
 
PI resistance is comprised of more than sixty mutations which include major protease, 
minor protease, accessory protease and Gag cleavage site mutations (Shafer et al., 
2008). Many PI mutations are accessory, compensating the replication impairment 
and susceptibility only in combination with other resistance mutations. Another PI 
resistance mechanism can be introduced by Gag cleavage site mutations and possibly 
other parts of the Gag that influence Gag-Pol processing (Cote et al., 2001; Dauber et 
al., 2002; Hoffman et al., 2003; Prabu-Jeyabalan et al., 2004 and van Maarseveen et 
al., 2006). 
 
1.3.3. HIV IN ARV drug resistant strains 
 
More than thirty integrase mutations are associated with ARV drug resistance to the 
recently approved Raltegravir, and Elvitegravir currently in clinical trials (Shafer et 
al., 2008). Mutations associated with the integrase enzyme are mostly within the 
binding site vicinity (Lataillade et al., 2007). IN mutations are associated with 
decreased drug susceptibility, loss of enzyme fitness and vice versa (Lataillade et al., 
2007). 
 
1.3.4. HIV entry ARV drug resistant strains 
 
The gp41 protein is associated with fifteen mutations that enhance resistance against 
enfuvirtide (Shafer et al., 2008). Enfuvirtide resistance is associated with mutations in 
HIV-1 gp41 codons 36 to 45 (according to HXB2 numbering), but is also associated 
with loss of virulence in mutant isolates (Marcelin et al., 2004; Menzo et al., 2004; Lu 
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et al., 2004; Sista et al., 2004; Mink et al., 2005; Melby et al., 2006 and Su et al., 
2006).  
 
ARV drug resistance mutations against CCR5 antagonists are poorly understood, but 
dose response curves suggest mutations in gp120 which may lead to enhanced viral 
binding to the CCR5 receptor in the presence of the CCR5 antagonist (Pugach et al., 
2007 and Westby et al., 2007). CCR5 antagonist ARV drug resistance was recently 
reported in a patient treated with Aplaviroc (Pfaff et al., 2010). These Aplaviroc 
resistant CCR5 mutations were also observed to introduce a tropism shift toward 
effector memory cells upon infection of primary CD4+ T cells (Pfaff et al., 2010). 
 
1.3.5. Transmission of HIV-1 ARV drug resistant strains 
 
Emergence of ARV drug resistant HIV-1 strains is an acknowledged concern in HIV-
1 treatment; but the transmission of drug-resistant (TDR) strains reported exacerbates 
the existing problem (Grant et al., 2002 and Little et al., 2002). Reports on TDR 
strains estimate their prevalence in developed countries where HAART is widely used 
to be at 10-20% (Grant et al., 2002; Ibe et al., 2002; Little et al., 2002; Simon et al., 
2002 and Shet et al., 2006). TDR has also been reported in regions where HAART 
usage is less common i.e. Asia and Africa (Barth et al., 2008 and Choi et al., 2008). 
These strains often exhibit resistance to several ARV drug classes and cross resistance 
within a class is also frequent. The emergence of TDR strains further complicates 
efforts to control the HIV-1 epidemic (Shafer et al., 1998; Hertogs et al., 2000 and 
Miller et al., 2001); hence the need for continued surveillance for TDR strains, and a 
continued search for new generation ARV agents.  
 
Assessment of temporal changes in the incidence of ARV drug resistant mutants 
through analysis of plasma viral load from individuals undergoing treatment suggest 
drastic decreases in the incidence of new HIV-1 ARV drug resistance (Gill et al., 
2010). Such decreases were associated with increased numbers of treated patients 
achieving virological suppression. The high rates of virological suppression over time 
were associated with the introduction of new HIV drugs and the continual assessment 
and improvement of HAART (Gill et al., 2010). These studies reinforce the ongoing 
need for novel therapeutic agents. 
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   1.3.6. Challenges in anti-HIV drug development and discovery 
 
Drug discovery and development is a lengthy process of approximately fifteen to 
eighteen years and with an estimated cost of US$800M to US$880M (Overby et al., 
2001 and Tollman et al., 2001; Cygnus, Business Consulting and Research. Vol 510, 
October 2005). The drug discovery process is characterised by high attrition rates 
with only 20% of drug leads entering clinical trials and only 10% of those achieving 
clinical registration. The attrition rate is mostly due to inadequate ADMET 
(adsorption, distribution, metabolism, excretion and toxicity properties; Eddershaw et 
al., 2000 and Dimasi et al., 2001). Large-scale chemical synthesis, pharmaceutical 
formulation, chemical stability and undesirable side-effects upon administration in 
vivo are additional factors that lead to increased attrition (Pauwels, 2006). 
Termination of a drug from the development process is normally due to various 
factors which are linked. For instance, toxicity might be the decisive reason for 
termination of a drug candidate from development, but factors such as long-term 
systematic exposure could be the underlying cause of the toxicity observed 
(Eddershaw et al., 2000). To avoid financial losses in drug discovery and 
development, pharmaceutical research and development uses rational approaches, 
with the logic being to reduce attrition in the costly downstream stages by screening 
agents for ADMET properties in the early stages of the discovery process - a “fail 
early and fail cheap” strategy (Eddershaw et al., 2000; Atterwill et al., 2002; Lin et 
al., 2003 and Robert, 2003). This is carried out through introduction of in silico 
techniques, physicochemical analysis techniques and biological assays that provide 
reasonable accuracy and preliminary prediction (Yu et al., 2003). 
 
1.4. Gold in medicine/Chrysotherapy   
 
Gold is a soft, malleable, lustrous yellow transition metal that can exist in a range of 
oxidation states, primarily the 0, 1+ and the 3+. The gold (0) state is the most stable, 
while gold(III)/3+ can be reduced to gold(I)/1+ which is easily reduced to gold(0); 
(Brown et al., 1982, Merchant, 1998). 
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The putative medicinal properties of gold have been known since antiquity with 
Arabic, Indian and Chinese physician’s prescribing gold preparations for the 
treatment of diverse ailments (Higby, 1982; Parish, 1992 and Tiekink, 2003). 
Chrysotherapy (the use of gold for medicinal applications; Fricker, 1996) in modern 
science was stimulated by Robert Koch’s 1890s observation of bacteriostatic effects 
of gold cyanide toward tubercle bacillus. Gold therapy was effectively introduced in 
the 1920s following suggestions of tubercle bacillus being the causative agent of 
rheumatoid arthritis (RA) which was later confirmed otherwise (reviewed by Fricker, 
1996). Studies suggest that gold compounds have potential in the treatment of cancer, 
HIV-1 infection and malaria (Shaw, 1999; Sun et al., 2004; Casini et al., 2008; 
Sannella et al., 2008). 
 
 1.4.1. Rheumatoid Arthritis (RA) 
  
In 1935, Robert Koch’s findings inspired Jacque Forestier to further investigate the 
use of gold compounds in the treatment of various arthritis ailments. These 
incorporated the treatment of psoriatic arthritis, juvenile arthritis, palindromic 
rheumatism and discoid lupus erythematosus as described by Champion et al., 1990. 
Early chrysotherapy included the use of sodium aurothiomalate and aurothioglucose 
to treat RA, a practice that lead to the discovery of the orally bioavailable drug 
auranofin in 1985 (reviewed by Fricker, 1996). Gold thiolates (Table 1.5) have been 
the principal gold compounds used in the treatment of arthritis but their mechanism of 
action is still unclear in part due to the lack of understanding of RA. The three widely 
used gold drugs, aurathiomalate, aurothioglucose and auranofin, have been shown to 
inhibit protein kinase C (Mahoney et al., 1989). Kinase C is a metallo-enzyme 
containing Zn2+ bound to cysteine (Cys) and histidine (His) residues which are 
essential for intracellular signal transduction through phosphorylation of serine (Ser) 
or threonine (Thr) residues on protein surfaces (Herlin et al., 1989 and Mahoney et 
al., 1989). Biochemical studies have shown that gold compounds act upon different 
stages of RA, one possibility was the interaction with peptides presented on the 
surface of T-helper cells by MHC-II molecules (De Wall et al., 2006). Such an 
interaction would prevent immunologic recognition and phagocytosis since RA is an 
autoimmune disorder (Best and Sadler, 1996). 
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Table 1.5: Gold thiolates used medicinally for Rheumatoid Arthritis treatment 
(modified using information from Sadler, 1976; Brown et al., 1980 and Jones et al., 
1996). 
Name Formula 
Myocrisin,  
Myochrisin,  
Mychrisis 
Sodium gold thiomalate 
[Na2AuStm], a variable mixture of the mono-(C4H4AuNaO4S) and 
disodium (C4H3AuNa2O4S) salts 
 
Solganol Sodium gold+ thioglucose; gold 4-aminomethylsulphonic-acid-2-
mercaptobenzene-1-sulphonic acid 
Sanocrysin,  
Sanochrisin,  
Crisalbine,  
Aurothion 
Sodium gold thiosulfate 
[Na3Au(S2O3)2] 
Allocrysine, 
Allochrysin 
Sodium gold thiopropanosulfonate 
Krysolgan Sodium gold 4-amino-2-mercaptobenzoic acid 
Auranofin 2,3,4,6-tetra-o-acetyl-1-thio-B-D-glucopyranoside; 2,3,4,6-tetra-O-
acetyl-1thio-B-D-Pyranosato-S-(triethylphosphine)-Au+ 
 
 
 
1.4.2. Anticancer activity of gold compounds 
 
The discovery of the anticancer properties of the platinum based drug cisplatin 
prompted a great deal of interest in the area of metal based cancer chemotherapy 
(Rosenberg et al., 1969). Research on possible chrysotherapy for cancer focused on 
gold(III) compounds; which led to the testing and discovery of auranofin’s anti-cancer 
activity in HeLa cell lines and P388 leukaemia cell lines in vivo (Simon et al., 1979; 
Simon et al., 1981; Simon et al., 1989). This was due to gold(III) compounds 
isoelectric square planar similarities to cisplatin, and therefore similar antitumor 
properties were expected. Studies have implicated compound-DNA interactions and 
inhibition of disease specific thiol-containing, cysteine protease cathepsins as possible 
mechanisms of action (Gabbiani et al., 2007 and Casini et al., 2008). In addition, the 
gold(III) compounds exhibit inhibition of the thioredoxin reductase and the associated 
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disregulation of the mitochondrial functions, which explains their apoptotic effects 
during cancer cell growth inhibition (Casini et al., 2008). Messori and co-workers 
have demonstrated the inhibition of cisplatin resistant cancer cell lines by gold(III) 
compounds (Messori et al., 2000); which suggests that gold compounds and cisplatin 
have a different mechanism of anticancer action (Messori et al., 2000, Gabbiani et al., 
2007). 
 
 1.4.3. Antimicrobial activity of gold compounds 
 
Gold compounds have in addition been investigated for activity against various 
microbial pathogens. For instance Novelli et al., 1999 has demonstrated biocidal 
activity of gold compounds against Escherichia coli (E.coli) ATCC25922, 
Pseudomonas aeruginosa (P.aeruginosa) ATCC 27853, Staphylococcus aureus 
(S.aureus) ATCC 25923 and ATCC 6538, and Staphylococcus epidermidis 
(S.epidermidis). Moreover, gold compounds also exhibit anti-fungal activity toward 
Candida albicans (C.albicans) ATCC 10231, Aspergillus niger (A.niger) ATCC 
16404 and Trypanosoma cruzi (T.cruzi; Sanchez-Delgado et al., 1993 and Novelli et 
al., 1999). Gold compounds have been shown to inhibit malarial pathogen such as 
Plasmodium falciparum (P.falciparum) and Plasmodium berghei (P.berghei); and 
some sexually transmitted infections such as Peptostreptococcus vaginalis 
(P.vaginalis; Sanchez-Delgado et al., 1996; Navaro et al., 1997 and Novelli et al., 
1999).  
 
 1.5. Potential chrysotherapy of HIV/AIDS 
 
 
Aurocyanide, a gold compound metabolite, has demonstrated inhibition of HIV-1 
proliferation in a cultured T-9 cell line at levels as low as 20nM and was noted for 
possible synergy in combination with other ARV drugs (Tepperman et al., 1994). 
Other gold compounds reported to exhibit anti-HIV-activities are 
bisthioglucose)gold(I) (bisAuTG), bis(thiomalate)gold(I) (bis-AuTM), and bis-
aurothiolate (bisAuTH). BisAuTG has been reported to prevent HIV-1NL4-3 infection 
in an MT4 cell line with an IC50 of 2.6±1.2µM (Okada et al., 1993). The current 
interest in HIV chrysotherapy was stimulated by a report that described the antiviral 
activity of gold compounds in a patient presented with AIDS and arthritis i.e. Reiter’s 
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syndrome and psoriatic arthritis patient accepting only gold treatment (Shapiro and 
Masci, 1996). The patient was not accepting antiretrovials but was treated for 
psoriatic arthritis with the gold-based drug, Auranofin which led to an increase in 
CD4+ T-cell count of the HIV/AIDS patient. The patient’s CD4+ T-cell counts 
increased from 270cells/mm3 to 400cells/mm3 five months after initiation of gold 
therapy with a CD4/CD8 T cell ratio of 0.47. The patient’s viral load measurement 
after two years following beginning of treatment was 1498 RNA copies/ml (Shapiro 
and Masci, 1996). 
 
  1.5.1. Possible HIV drug targets for gold compounds.  
 
Possible HIV-1 drug targets for gold compounds include inhibition of viral 
adsorption, inhibition of viral fusion, inhibition of RT by allosteric binding and active 
site binding (Blough et al., 1989; Okada et al., 1993). Gold compounds have been 
observed to inhibit nuclear factor kappa beta (NF-кβ) signalling pathway (Okamoto 
and Wong., 1986; Yang et al., 1995; Traber et al., 1998; Jeon et al., 2000) but since 
this pathway is not unique to HIV-1; it is therefore not a good target in that there may 
be toxicity implications. The mechanism of HIV-1 inhibition by gold compounds 
could be associated with gold’s affinity for proteins. Gold-based compounds have 
previously been shown to interact with naturally occurring thiols on unpaired 
cysteines (i.e. Cys532 of HIV-1 gp41) and glutathione residues on the surface of 
proteins (Shaw, 1988; Shaw, 1989).  
 
 1.5.2. Viral entry inhibition 
 
Bis(thioglucose)gold(I) has been reported as an HIV-1 entry inhibitor (Okada et al., 
1993). It was proposed that the compound undergoes gold(I) ligand exchange with 
thiol groups such as Cys532 in the amino terminus of gp41 of HIV-1NL4-3, which are 
exposed on the surface. This interaction introduces conformational changes in the 
fusion peptide which releases gp120 from the surface of the virion (Okada et al., 
1993). Such data directly implicated viral infectivity as a possible anti-HIV-1 drug 
target for gold-based compounds (Okada et al., 1993). 
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1.5.3. HIV-1 RT inhibition 
 
Aurothioglucose was shown to be an effective inhibitor of HIV-1 RT in cell lysates, 
inhibiting the initiation and elongation of viral cDNA chains (Blough et al., 1989). In 
addition, an aurothioglucose metabolite bisAuTG was later observed to exhibit anti 
HIV-1 RT activity (Okata et al., 1993). More recently Sun et al., 2004 demonstrated 
in vitro HIV-1 RT inhibition by gold(III) porphyrins following reports of in vitro 
HIV-1 inhibition by heme and some synthetic metalloporphyrins (Staudinger et al., 
1996 and Argyris et al., 1999); with [AuIII(TMPyP)]Cl5 demonstrating the most 
potent effects (IC50 = 0.31µM) as shown in Table 1.6 (Sun et al., 2004).  Fonteh et al., 
2009 has recently reported HIV-1 RT inhibition by gold based compounds at 
concentrations higher than 10µM. 
 
Table 1.6: Previously reported gold complexes IC50s against HIV-1 RT (Sun et al., 
2004). 
Compound IC50±STDev (µM) 
[AuIII(TMPyP)] 0.31±0.05 
Na4[AuIII(TPPs)]Cl 0.57±0.09 
[AuIII(TPP)]Cl 28.4±1.8 
[AuIII(salen)]+ 0.33±0.03 
[AuIII(dcbpb)]+ 0.47±0.09 
 
 
1.5.4. Gold compounds inhibit the NF-κß signalling pathway 
 
NF-кβ is an inducible cellular transcriptional factor that regulates a wide variety of 
cellular and viral genes with demonstrated ability to activate HIV-1 gene expression 
(Baeuerle and Baltimore, 1988; Okamoto et al., 1990; 1997 and Hayashi et al., 1993). 
NF-кβ exists in the cytoplasm complexed with an inhibitory molecule inhibitor kappa 
beta (Iкβ). Upon stimulation by virus/tumour necrosis factor alpha (TNF-α), the 
inhibitor molecule Iкβ dissociates from the complex allowing NF-кβ translocation to 
the nucleus where it site specifically binds to DNA (Baeuerle and Baltimore, 1988; 
Ghosh and Baltimore, 1990; Barnes et al., 1997 and May et al., 1998). In latently 
infected cells, NF-кβ binding to DNA induces the transcription of HIV-1 genes 
including tat, which leads to an explosive increase in viral replication (Okamoto and 
Wong, 1986 and Okamoto et al., 1989). The gold compound aurothioglucose has been 
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shown to inhibit the dissociation of the NF-кβ/Iкβ complex in OM101 and Ach2 cell 
lines latently infected with HIV-1 (Traber et al., 1998). Other studies have 
demonstrated inhibition of the DNA-binding ability of NF-кβ through a gold 
compounds redox mechanism and by blocking the Iкβ kinase enzyme known to 
phosphorylate the Iкβ (Yang et al., 1995 and Jeon et al., 2000). 
 
  1.5.5. Gold compounds as potential pro-drugs 
  
Gold(III) thioglucose has been reported as an HIV RT inhibitor although it’s been 
observed not to readily enter cells. Gold compounds are largely known to form 
metabolites such as [Au(CN)2]- which enhance their cellular (in H-9 cells) uptake, and 
as a result sufficient gold accumulates for viral inhibition (Roy et al., 1994). Studies 
based on in vitro experiments monitoring intestinal uptake of auranofin have 
demonstrated that it is a metabolite of the drug that crosses the intestinal wall 
(Tepperman et al., 1984). Other studies identified dicyanogold(I)/[Au(CN)2]- as the 
primary metabolite in patients accepting treatment with sodium gold thiomalate and 
gold thioglucose (Elder et al., 1993). These gold compounds are known to enter cells 
through transmembrane transport of their apparent metabolites, which are probably 
formed as a result of their binding to serum proteins to which their affinity is evident. 
For instance, gold compounds have been reported to interact with the soft ligands i.e. 
thiolates and phosphines on human serum albumin (HSA), horse heart cytochrome c, 
bovine ubiquitin, hemoglobin and metallothionein (Shaw, 1989; Best and Sadler, 
1996 and Casini et al., 2006). Moreover, 80% of gold is found bound to HSA 
subsequent to exposure (Casini et al., 2006). These protein-drug interactions are 
possibly the cause of gold compound breakdown which creates the inhibitory gold 
metabolites. Therefore, such data suggests a pro-drug effect, and offers a possible 
mechanism of action. 
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1.6. Summary 
 
In South Africa, the country most affected by the HIV/AIDS pandemic, greater 
emphasis and research efforts should be focused on developing the next generation 
and/or novel anti-HIV agents for use locally. This study uses a short gun approach to 
elucidate gold compounds as potential inhibitors of HIV-1. Theoretical approaches 
are used to assess bioavailability of test compounds and in vitro tests are carried out to 
identify inhibitors and their biological properties. Structures of HIV-1 inhibitors 
identified will later be used as a base to rationally design second generation inhibitors 
with improved biological profiles. 
 
1.7. Hypothesis 
 
Theoretical and experimental analysis of a collection of gold-based compounds will 
aid identify good anti-HIV-1 inhibitors and their mechanism of action.  
 
1.8. Objectives 
 
Gold-based compounds were previously observed to inhibit HIV-1 replication, 
therefore it was decided that a blind chemical screen would be carried out on our 
existing collection. The overall objective of this study is to systematically analyse 
gold-based compounds as inhibitors of HIV-1, and this will be accomplished through 
fulfilment of the following aims:  
• To theoretically analyse all compounds within the library through on-line 
software and via the Lipinski Rule of Five (RO5).  
• To experimentally determine and evaluate the solubility, cytotoxicity and 
antiretroviral activity of each of the compounds. 
• To narrow down the mechanism of action for compounds with antiretroviral 
activity.  
• To closely correlate all data with compound structures, and provide 
commentary on useful characteristics.  
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CHAPTER 2 
MATERIALS AND METHODS 
 
 
2.1. Synthetic chemical compounds and reagents used in this study 
 
2.1.1. Synthetic chemical compounds investigated 
 
From an in-house collection of 150 gold compounds available at Mintek, 45 gold-
based compounds were selected for further analysis in this study. These 45 
compounds arise from 5 compound families (see Tables 2.1 to 2.5 below) and were 
selected as a representative sample of the 150 gold compounds. The compounds 
exhibit structural similarity within the 5 compound families but are structurally 
diverse between compound families. 
 
2.1.1.1. Chemical structures of gold compounds Autek Biomed (AB) 01-AB04 
(Series 1) 
 
This Series consist of four gold(I) triphenylphosphine complexes from metallocene 
derivatives (Fe and Ru), obtained from Professor James Darkwa’s laboratory at the 
University of Johannesburg, South Africa (Table 2.1). 
 
Table 2.1: Chemical structures of gold compounds in Series 1 (AB01-AB04) 
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AuCl
 
 AB02         
Ru
P
P
O
O
Ph
Ph
Au ClPh
Ph
AuCl
 
AB03       
Ru
P
P
N
Ph
Ph
Au ClPh
Ph
AuCl
 AB04              
Ru
P
P
HN
O
Ph
Ph
Au ClPh
Ph
AuCl
O
OH
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2.1.1.2. Chemical structures of gold compounds AB05-AB11 (Series 2)   
 
The seven compounds were a kind gift from Professor Maria A. Cinellu of the 
Universita di Sassari, Italy (Table 2.2). This Series of compounds contain NNOO 
coordinated gold(III) complexes. These complexes are PF6- salts (with the exception 
of AB09, AB10 and AB11), known to confer low solubility in ionic liquids. 
 
Table 2.2: Chemical structures of gold compounds in Series 2 (AB05-AB11) 
 
AB05 AB06           
 
 
 
 
AB07 
 
 
AB08  
 
 
AB09 
 
AB10  
 
 
AB11 
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2.1.1.3. Chemical structures of gold compounds AB12-AB13 (Series 3) 
 
The two compounds AB12 and AB13 used in this study were synthesised in Professor 
Antonio Laguna‘s Laboratory at the Universidad de Zaragoza, Spain (Table 2.3). 
They are a small gold(I) phosphine and a thiolate complex, with Chlorine as 
coordinated counter ion and triflate and tetrafluorborate salts. 
 
Table 2.3: Chemical structures of gold compounds in Series 3 (AB12-AB13) 
 
      
HN N
N NPPh2
AuCl
 
 
AB12 
 
 
C
S
BF4-
Au Au
Ph3P PPh3
CH COOHN
H
CMe
O
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AB13 
 
 
2.1.1.4. Chemical structures of gold compounds AB14-AB38 (Series 4)   
 
This Series of 26 compounds (AB14-AB38) were synthesised in Prof H.G. 
Reubenheimer’s Laboratory at the University of Stellenbosch, South Africa, and they 
consist of some mono- and bridge- phosphine and nitrogen-based gold(I) complexes 
(Table 2.4). These compounds vary in the length of the hydrocarbon bridge, the nature 
of the phosphine substituent and nitrogen-rich heterocycle (purines, azoles). 
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Table 2.4: Chemical structures of gold compounds in Series 4 (AB14-AB38)  
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Mol. Wt.: 1086.66
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2.1.1.5. Chemical structures of gold compounds AB39-AB45 (Series 5)   
 
This Series of seven compounds was synthesised in Professor James Darkwa 
laboratory at the University of Johannesburg, South Africa, and consists of gold(III) 
complexes of substituted pyrazol and pyridine (as bidentated nitrogen donors) linked 
with a methylene or ethylene bridge (Table 2.5); and a ferrocene diphosphine gold(I) 
complex has also been included (AB45).  
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Table 2.5: Chemical structures of gold compounds in Series 5 (AB39-AB45) 
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2.1.2. Cell lines, viral isolates, and recombinant enzymes used in this study 
 
The following reagents were obtained through the NIH AIDS Research and Reference 
Reagents Program, Division of AIDS, NIAID, NIH: PM1 cells from Dr. Marvin Reitz 
(Catalogue # 3038); HIV-1HXB2 reverse transcriptase (p66>Q/p51) from Dr Stuart Le 
Grice (Catalogue # 2897); HIV-1HXB2 reverse transcriptase/ M184V from Dr. 
Vinayaka Prasad (Catalogue # 3195); HIV-1Ba-L from Dr Suzanne Gartner (Catalogue 
# 510); and the HIV-1NL4-3 from Dr Malcolm Martin (Catalogue # 2479) 
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(https://www.aidsreagent.org).  The purified recombinant integrase enzyme utilised in 
this study was prepared within our laboratory from the expression vector 
pINSD.His.Sol (Catalogue # 2958).  
 
2.2. Theoretical screening of synthetic compound collection 
 
2.2.1. Osiris Molecular Property Explorer 
 
The gold compounds described in section 2.1.1 were screened theoretically using the 
Osiris Molecular Property Explorer (JAVA-based sketch program) available online at 
http://www.organic-chemistry.org/prog/peo/ accessed 07-09-2010. The compounds 
were assessed for several chemical, physicochemical and toxicity parameters through 
analysis of chemical structures. Specifically, these included water-octanol partitioning 
coefficiency (cLogP), aqueous solubility (LogS), molecular weight, tumourigenicity, 
mutagenicity, irritancy, possible effects on reproduction, fragment-based drug 
likeness and the overall drug-like score. The LogP evaluation uses a reference training 
set of approximately 368 different atom types to evaluate properties such as atomic 
number and ring membership thus predicting hydrophilicity; and approximately 5000 
experimentally determined logP values. The compound LogS prediction uses 
approximately 2000 experimentally determined and atomic properties (this excludes 
ring membership) used in prediction of LogP as an optimizing training set. The 
assessment of toxicity uses 3300 clinically approved drugs and a set of pre-computed 
structural fragments from the Registry of Toxic Effects of Chemical Substances 
(RTECS) as a reference database. Predicted outcomes are valued and colour coded, 
the red colour represents high risk toxicity fragments and the green is interpreted as 
drug conform behaviour. Drug-like properties for the 45 compounds were evaluated 
using a reference database of 3300 approved drugs and 15000 non-drug-like Fluka 
chemicals by measuring occurrence frequency of specific fragments in the compounds 
chemical structure. The final drug score combined all parameters assessed to predict 
the compounds overall drug potential.  Following the Osiris Property Explorer 
assessment of compound structures the drug-likeness scores were analysed using 
Table 2.6 below. 
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Table 2.6: Analysis of Osiris Molecular Property Explorer results  
Drug-likeness score Interpretation of Score 
1 Desired score 
0.7-0.99 Good drug-likeness score 
0.4-0.69 Intermediate drug-likeness score 
≤0.4 Poor drug-likeness score 
   
   
2.2.2. Lipinski’s Rule of Five (Ro5) 
 
All 45 gold compounds were assessed theoretically in accordance with the four rules 
of the Lipinski’s Ro5. Lipinski’s Ro5 is a rule of thumb used to predict the drug-
likeness of chemical compounds.  
 
The Rule of Five requires: 
 : Compounds hydrogen bond donors less than 5 (OH and NH groups) 
 : Compounds hydrogen bond acceptors less than 10 (N and O atoms) 
 : Compounds molecular weight less than 500g/mol 
 : Compounds partition coefficient (LogP) less than 5 
 
The compounds were analysed by visual inspection to determine the number of 
hydrogen donors and acceptors while the molecular weight and the LogP values were 
predicted by application of the Osiris Property Explorer detailed in Section 2.2.1. All 
rules are weighed equally; with a score value of one, thus the score value of each 
compound is out of a total of four.  
The scores were interpreted in accordance with the NIAID – Division of AIDS, HIV / 
OI / TB Therapeutics Database (http://chemdb.niaid.nih.gov/ accessed 07-09-2010) as 
in Table 2.7 below. 
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Table 2.7: Analysis of Osiris Molecular Property Explorer results according to the 
NIH 
Score = Number of Parameters Interpretation of Score 
4 Good 
3-1 Intermediate 
0 Poor 
 
 
2.3. Aqueous solubility of synthetic compounds 
 
The aqueous solubility was adapted from a protocol by Millipore Corporation, 
Billerica, MA USA (“Determination of aqueous compound solubility using a 96-well 
filter plate to remove precipitated solids prior to UV/VIS Spectroscopic analysis” 
available at http://millipore.com/techpublications/tech1/pc2445en00 accessed 07-09-
2011). Compounds were initially prepared at a stock concentration of 10mg/ml in 
dimethyl sulfoxide (DMSO; Sigma Aldrich, St Louis MO, USA) and a standard curve 
for each compound was established using concentrations of 500µM, 200µM, 50µM, 
12.5µM and 3.13µM. Chloramphenicol (Sigma Aldrich, St Louis MO, USA) was 
included as a control compound. All compound concentrations were prepared in a 
filtered 80:20 (universal buffer, pH7.4: acetonitrile; ACN) solution in 2.2ml 96-deep-
well Master-blocks (Greiner Bio-One, Germany) keeping the DMSO concentration 
below 5% per sample. The universal buffer was prepared using high purity water, 
45mM ethanolamine, 45mM potassium dihydrogen phosphate and 45mM potasium 
acetate; which were respectively purchased from Sigma Aldrich, St Louis MO, USA; 
Associated Chemical Enterprises Pty Ltd, South Africa; Sigma Aldrich, St Louis MO, 
USA and Merck, Germany. The assay was left on a shaker (100-300 rpm) for 30 
minutes prior to transfer into Greiner UV-StarTM analysis plates and spectrometric 
detection (X-MarkTM Microplate Spectrophotometer, Bio-Rad Laboratories, Inc. 
USA) at 260nm to 500nm; from which a standard curve for each compound was 
determined. 
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After the standard curve was drawn, compounds (500µM) were prepared in universal 
buffer (pH7.4) in 200µl volumes in Millex®-LCR filter units, and kept on a shaker 
(100-300 rpm) for ninety minutes. The samples were vacuum filtered into deep-well 
Master-Blocks, and subsequently transferred (160µl) to the UV-StarTM analysis 
plates; wherein 40µl/per sample ACN was added. The assay was quantified using 
spectrophotometric (X-MarkTM microplate spectrophotometer) detection at each 
compound’s optimal wavelength. The determined optimal absorbance was divided by 
the slope of the corresponding compound’s standard curve, and then multiplied by the 
dilution factor (1.25) of ACN as shown in the formula below. 
 
Aqueous solubility = (Amax filtrate/ Slope) x 1.25  
 
Low aqueous solubility was defined as gold compound concentrations less than 
200µM that had dissolved into medium; concentrations between 200µM to 500µM 
were considered moderate and good solubility was compound solubility greater/equal 
to 400µM. 
 
2.4. Cytotoxicity assays of synthetic compounds 
 
 
2.4.1. Gold compounds cytotoxicity in a PM1 cell line 
 
Cytotoxicity testing for all 45 compounds was carried out in PM1 cell lines at a 
concentration of 1x105 cells/ml. The cell concentration was determined using the 
trypan blue exclusion (Gibco/Invitrogen, Mowbray, South Africa) method. Cells were 
initially prepared in RPMI complete media supplemented with 10% foetal calf serum 
(FCS), 0.2% gentamycin and 0.2% streptomycin/penicillin (Sigma Aldrch, St Louis 
MO, USA); and were stabilized (100µl/well) for an hour in a 37°C, 5% CO2 
incubator. Eight serial dilutions (400-3.125µM) of each compound were prepared in 
RPMI complete media and plated at 100µl/well to the incubated cells. After 96 hours 
of incubation at 37°C and 5% CO2, cell viability was assayed by addition of 10µl 
CellTiter 96 Aqueous One Solution Assay to each well (Promega, USA). The assay 
was read at an absorbance wavelength of 490nm on a multi-plate reader (BP800, 
BioHIT, Finland) after two hours. Cytotoxic concentration (CC50) was determined as 
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the concentration of the test substance required to reduce cell viability by 50% using 
Origin 6.1 software (Origin Lab Corporation, Northampton, MA). Each experiment 
was carried out in triplicate. 
 
2.4.2. Cytotoxicity assays in peripheral blood mononuclear cells (PBMCs) 
 
 
The following assay was carried out at the Southern Research Institute, Birmingham, 
USA, following submission to the NIAID AIDS Research and Reference Reagent 
Program. Only compounds AB05-AB11 were screened using the following protocol 
because they had demonstrated considerable direct RT inhibition (see section 2.5.2). 
Fresh human blood was obtained from the Biological Specialty Corporation (Colmar, 
Pennsylvania, USA) from donors screened seronegative for HIV and HBV. PBMC 
isolation was carried out using the standard Ficoll-Hypaque density gradient 
(Lymphocyte separation medium, Cell Grow #85-072-CL, density 1.078 ± 
0.002mg/ml). For the standard PBMC cytotoxicity assay, PHA stimulated cells were 
pooled from at least two donors. The PBMCs were prepared to a final concentration 
of 1x106 cells/ml and 50µl/well (5x104 cells/well) PBMCs were seeded in ninety-six 
well microplates (round-bottom). Compounds were evaluated using a 200µM high-
test concentration with 8 additional serial half-log dilutions. The assay was incubated 
for 7 days in a 37°C, 5% CO2 incubator. Cytotoxicity studies included a control 
NRTI, azidothymidine (AZT; 200µM-0.193µM) in addition to the AB05-AB11 test 
compounds, plus media without cells control. Compound cytotoxicity and cell 
viability were measured using the Molecular Devices SPECTRAmax plate reader at 
490/650nm following addition of 20µl-25µl MTS (CellTiter 96 Reagent, Promega. 
USA) and 4 hours of incubation at 37ºC. 
 
2.5. Direct enzyme activity of synthetic compounds 
 
All 45 gold compounds were tested in a range of assays to determine if they exhibited 
direct enzyme activity against HIV-1 IN and RT. 
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2.5.1. Direct HIV-1 integrase strand transfer assay 
 
The direct HIV-1 IN strand transfer assay was set up and performed to determine 
whether any of the 45 test compounds were capable of preventing the incorporation of 
donor DNA into target DNA by IN. 
 
The donor DNA (biotin 5’- ACCCTTTTAGTCAGTGTGGAAAATCTCTAGCA-3’ 
and 5’-ACTGCTAGAGATTTTCCACACTGACTAAAAG-3’; Inqaba Biotech 
Pretoria, South Africa) was annealed by heating to 95ºC for 5 minutes and then cooled 
to room temperature. The working concentration of donor DNA (0.15µM) was 
prepared in buffer A (10mM Tris-HCl, 0.1M NaCl2; pH 7.2); before transfer (100µl) 
into streptavidin coated microplate (MP) wells. The reaction was sealed and incubated 
for an hour at room temperature (shaking at 50rpm). Subsequently, the supernatant 
was aspirated and wells were washed three times with 300µl 1XPBS buffer. 
Recombinant integrase (1µM) prepared in buffer B (20mM Hepes, 75mM NaCl2, 
10mM MgCl2, 2µM ZnCl2, 10mM MnCl2, 1% glycerol; pH 6.8) was subsequently 
transferred into each well, sealed and incubated for thirty minutes (shaking at 50rpm). 
The wells were washed 2 times with buffer B, and subsequently 90µl of each of the 
gold compounds (10µM) prepared in buffer B were transferred into duplicate or 
triplicate wells. The assay was sealed and incubated for thirty minutes at 37°C. A 
concentration of 2.5µM target DNA (5’-TGACCAAGGGCTAATTCACT-3’ 
Fluorescein and 5’-AGTGAATTAGCCCTTGGTCA-3’ Fluorescein; Inqaba Biotech, 
Pretoria, South Africa) was prepared, added at 10µl/well and then incubated for an 
hour at 37°C.  The wells were washed three times (ten minutes each at 37°C) with 
300µl buffer C (0.03M sodium citrate, 0.3M NaCl2; pH 7.0). Monoclonal anti-FITC-
alkaline phosphatase sp (Sigma Aldrich, St Louis MO, USA) working solution was 
prepared 1:10 000 in buffer D (50mM Tris-HCl, 150mM NaCl2, 0.05% Tween 20; pH 
7.4) and added at 200µl per well. The plate was incubated for two hours at 25°C; and 
then washed three times as before in buffer D (without 0.05% Tween 20). A Sigma 
FASTTM p-Nitrophenylphosphate substrate prepared according to manufacturer’s 
(Sigma Aldrich, St Louis MO, USA) instructions was added to the wells (200µl). The 
assay was incubated for thirty minutes in 37°C and quantified using a multiplate 
reader at a wavelength of 405nm (xMARKTM, Bio-Rad Laboratories Inc).    
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2.5.2. Direct HIV-1 RT assay 
 
The direct HIV-1 RT assay was performed to determine whether any of the 45 test 
compounds were inhibitors of the polymerase activity of HIV-1 RT.  
 
The 45 gold compounds were tested in a direct HIV-1 RT assay at 10µM according to 
manufacturer’s instructions (Roche Diagnostics. Reverse Transcriptase Assay, 
colorimetric, version May 2006). Compounds that showed good inhibition at 10µM 
were then tested at 1µM; and where good inhibition was retained further testing was 
performed at 0.5µM and subsequently 0.1µM. Briefly, HIV-1 RT was initially 
reconstituted in 250µl autoclaved high purity water to a final concentration of 2ng/µl, 
and stored at -20°C in aliquots until used. The reaction mixture was prepared by the 
addition of 430µl autoclaved high purity water to the template, followed by addition 
of 1ml incubation buffer (ready-to-use solution) to a separate vial of nucleotides. A 
100µl template solution was added to the prepared nucleotide solution to make up the 
final reaction mixture. The enzyme-linked immunosorbent assay (ELISA) protocol 
began with the preparation of solution mixture which consisted of the following: 20µl 
of each of the 45 gold compounds (at the desired final concentration), 20µl reaction 
mixture (10µM dUTP/dTTP, template/primer hybrid) and 20µl HIV-1 RT enzyme 
(2ng/µl) which was incubated for an hour at 37°C. After incubation, the samples were 
transferred into the wells of micro-plate (MP) modules, covered with foil and then 
incubated at 37°C for an hour. During the second incubation anti-digoxigenin-
peroxidase (DIG-POD) working solution was prepared to a final concentration of 200 
milliunits per milliliter (mU/ml); e.g. 50µl antibody solution and 4.95ml of conjugate 
dilution buffer). After one hour incubation, the solutions were removed from the wells 
and the wells were washed five times with 250µl washing buffer (prepared by the 
addition of 225ml autoclaved high purity water to stock solution) per well. Thereafter 
200µl anti-DIG-POD working dilution was added to each well, covered with foil and 
incubated for an hour at 37°C. During incubation an 2,2’-azino-bis (3-
ethylbenzthiazoline-6-sulphonic acid) (ABTS) substrate solution was prepared by 
dissolving an ABTS tablet in 5ml substrate buffer. Following a one hour incubation 
the wells were washed as described previously and 200µl of ABTS substrate solution 
was added to each well. Photometric detection was performed using a multiplate 
reader (BP800, BioHIT, Finland) at a wavelength of 405nm with a reference 
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wavelength of 490nm after a 15 minute incubation. This assay was carried out with a 
positive control (20µl lysis buffer, 20µl RT and 20µl reaction mixture), a negative 
control (40µl lysis buffer and 20µl reaction mixtures) and NNRTI Efavirenz was used 
as a control compound. The assay was performed in triplicate and Origin 6.1 software 
was used to determine inhibitory concentrations (IC50) required to inhibit 50% of 
HIV-1 RT activity. 
 
2.5.3. Direct RT assay: 10% FCS 
 
Testing of the influence of 10% FCS on potency of the selected compounds AB05-
AB08 was carried out at 10µM using the HIV-1 RT assay according to manufactures 
instructions, as described in section 2.5.2 with specific modifications. In particular; 
FCS (Highveld Biological, Johannesburg, South Africa) was prepared to 10% of the 
final sample volume (60µl) within the 20µl drug compound mixture. The 10% FCS 
concentration was used as it represents the serum protein concentration used in cell 
(PBMCs) based antiviral assays (see section 2.6). The rest of the assay was carried out 
as before in duplicate experiments of triplicates; and included the provided positive 
control (20 µl lysis buffer, 20µl RT and 20µl reaction mixture), the provided positive 
control containing 10% FCS and a negative control (40µl lysis buffer and 20µl 
reaction mixture).  
 
 
2.5.4. Direct HIV RT assay: 4.5mg/ml human serum albumin (HSA)  
 
Compounds AB05-AB08 were investigated at concentrations of 10µM, 1µM, 0.5µM 
and 0.1µM or 100µM, 75µM, 50µM, 25µM, 10µM, 0.5µM and 0.1µM depending on 
potency using the HIV-1 RT assay as determined in section 2.5.2 with specific 
modifications. In particular, the addition of 4.5mg/ml HSA (Sigma Aldrich, St Louis, 
MO, USA) to a final sample volume of 120µl was prepared with the test drug 
compound solution, RT and reaction mixture. The 4.5mg/ml HSA concentration was 
used as it represents 10% of the serum protein concentration normally found in the 
plasma of AIDS patients (Cobertt et al., 1999). The rest of the assay was carried out 
as before (section 2.5.2) in triplicate. The change (n-fold) in 50% inhibition of RT 
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activity (FCIC50) relative to the HSA-free assay was used to determine the effect of 
the serum protein on compound inhibition. 
 
2.5.5. Direct RT: Inhibition of polymerase (p66 subunit) activity 
 
Testing of four compounds (AB05-AB08) for HIV-1 p66 inhibition was carried out at 
a 10µM concentration using the direct HIV-1 RT assay as described in section 2.5.2 
with some modifications. Specifically, this involved the addition of the RT mutant 
[(subtype B HIV-1HXB2 reverse transcriptase (p66>Q/p51)] which lacks RNaseH 
activity. The use of this specific enzyme requires the addition of substrate enhancer to 
ABTS substrate prior to photometric detection at wavelengths 405/490nm after thirty 
minutes using a multiplate reader (xMARKTM, Bio-Rad laboratories Inc). These 
assays were carried out in triplicate experiments with a positive control (20µl lysis 
buffer, 20µl wild type RT and 20µl reaction mixture) and a negative control (40µl 
lysis buffer and 20µl reaction mixture).  
 
2.5.6. Inhibition of a 3TC/Lamivudine resistant mutant 
 
The four compounds (AB05-AB08) were also investigated for activity against drug 
resistant RT at a 10µM concentration using the direct RT protocol that was described 
in section 2.5.2 with special modifications. The specific modifications included the 
use of the HIV-1HXB2 reverse transcriptase/ M184V mutant. This mutant HIV-1 RT is 
known to demonstrate 3TC/lamivudine resistance. The assay was quantified using 
photometric detection at 405/490nm by a multiplate reader (xMARKTM, Bio-Rad 
Laboratories Inc) after 15 minutes. The assays were carried out in triplicate 
experiments; with a positive control comprising of 20µl lysis buffer, 20µl RT and 
20µl reaction mixture and a negative control (40µl lysis buffer and 20µl reaction 
mixture).  
 
2.6. Anti-HIV activity of gold compounds AB05-AB11 in PBMCs  
 
The antiviral assays for the seven compounds (AB05-AB11) were carried out at the 
Southern Research Institute, Birmingham, USA following submission to the NIAID 
AIDS Research and Reference Reagent Program. PBMCs were isolated as described 
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in section 2.4.2. The standard antiviral PBMC assay was performed as follows: PHA 
stimulated PBMCs were pooled from at least two HIV/HBV seronegative donors. 
PBMCs were prepared to a final concentration of 1x106 cells/ml and were pre-treated 
with viral stock at a multiplicity of infection of 0.1. Viral isolates used in each assay 
were the HIV-1 subtype B HIV-1Ba-L and the HIV-1NL4-3 isolates. The infected cells 
were then seeded at 50µl/well (5x104 cells/well) in 96 well microtiter plates; and the 
compounds were evaluated using a 200µM high-test concentration with 8 additional 
serial half-log dilutions. Each assay contained AZT as a positive control antiviral 
measure (1µM) and cells plus virus as a negative control; and was maintained for 7 
days in a 37°C, 5% CO2 incubator. The antiviral assay was quantified using an RT 
assay adapted from Buckheit et al., 1991. Briefly, a reaction mixture was prepared by 
mixing titriated thymidine triphosphate (125µl 1.0M DTT, 40µl 1.0M MgCl2, 3H-
TTP, 80Ci/mmol, NEN; Pharmacia, Inc.) with a primer solution (150µl poly Ra 
(20mg/ml), 0.5 oligo Dt (20units/ml) and 5.35ml sterile dH2O) and transferred (10µl) 
into round bottom plates. Fifteen microliters of virus-containing supernatant was 
subsequently added to the reaction mixture and incubated at 37°C for an hour. 
Thereafter, reaction mixtures were spotted onto DE81 filter-mats (Wallac, Turku, 
Finland) and washed five times in 5% sodium phosphate buffer or 2X saline-sodium 
citrate (SSC) (Life Technologies, Carlsbad, USA) for five minutes each; and two 
times for one minute each in dH2O, followed by a two times wash for a minute in 
70% ethanol prior to drying. Incorporated radioactivity (counts per minute, CPM) was 
quantified using standard scintillation techniques. 
 
2.7. 1H NMR measurement of protein-synthetic gold compound interactions in 
physiological medium 
 
The compounds AB05-AB11 were selected for investigation following their 
successful inhibition of RT (Section 2.5.2). The final concentration of each test 
compound included DMSO-d6 (Sigma Aldrich, St Louis MO, USA) of maximum 5% 
in deuterated PBS (dPBS). The dPBS (pH7.4) contained: 3.2mM Na2HPO4, 0.5mM 
KH2PO4, 1.3mM KCl and 135mM NaCl dissolved in deuterated oxide (Sigma 
Aldrich. St Louis, USA). The pH was adjusted to pH7.4 using deuterated chloride 
(Sigma chemical. St Louis, USA). The ability of HSA to interact with each compound 
was investigated at 1mM in a final volume of 500µl PBS and test compound (1mM). 
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Spectra were recorded at 300K using the 400MHz Bruker Avance Spectrometer 
equipped with a broadband inverse (BBI) 5mm probe. Proton chemical shifts were in 
parts per million (ppm), and were referenced to residual solvent resonances. Protein 
signals were almost undetectable due to their relatively low concentrations and the 
T2-filter contained in the pulse program (stdwsrf.ak, avance version 00/02/07). Water 
suppression was achieved by a Watergate W5 pulse sequence with gradients using 
double echo (Liu et al., 1998). The intensities of the DMSO signal in all the 
references spectra recorded (1H NMR) were matched in each sample, in order to make 
signal change comparable. Any changes in 1H NMR spectra of compounds were 
monitored using the reference spectra (off-resonance) of the saturation transfer 
difference (STD). Possible interactions between HSA and the gold compounds were 
investigated using NMR’s STD technique.  
 
2.8. Measurement of synthetic gold compound stability in biological medium 
 
The synthetic gold compounds AB05-AB08 were prepared at 1mM in sterile 10% 
RPMI-1640 complete (RPMI, 10% FCS, 0.002% gentamycin and 0.002% 
streptomycin/penicillin) media supplemented with 10% deuterated oxide (D20; Sigma 
Aldrich, St Louis MO, USA) in final volume of 440µl. Thereafter, the samples were 
transferred to UV-irradiated (thirty minutes) NMR tubes prior to NMR spectral 
reading at 298K using the 400MHz Bruker Avance Spectrometer provided with a BBI 
5mm probe. Proton chemical shifts were analysed in ppm referenced to residual 
solvent resonances. 
 
Observation of changes in each compounds spectra required water suppression due to 
the aqueous composition of the sample. Thus, several water suppression methods such 
as Watergate, ID water suppression by pre-saturation and ID water suppressed nuclear 
overhauser effect (NOE) with gradients were used. 
 
2.9. Statistical Analysis 
 
All experiments were conducted in at least triplicate with bioligal duplicates (n ≥ 6) 
and the analysis of data was carried out with the use of Microsoft (MS) Office 
ExcelTM 2003, version 11.  Averaged results were evaluated for inaccuracy by the 
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determination of standard deviations by using MS Office Excel. The Origin 6.1 
software was used in the determination of CC50s and IC50s. Statistical analysis was 
carried out by the application of the Students t-test from simple interactive statistical 
analysis (SISA) at a 95% confidence interval (CI) available online at 
http://home.clara.net/sisa/ accessed 07-09-2011. 
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CHAPTER 3 
RESULTS 
 
 
3.1. Theoretical screening of synthetic compounds 
 
Overall, theoretical screening results as measured through the Osiris Property 
Explorer were obtained for 34 compounds, and included predictive analysis of drug 
compound lipophilicity, aqueous solubility, toxicity, drug-likeness and drug-like 
score. In addition, Lipinski’s Ro5 predicted oral bioavailability data for all 45 
compounds tested. 
 
3.1.1. Osiris Property Explorer 
 
Results from the Osiris Property Explorer for 34 of the 45 compounds are shown in 
Table 3.1. The remaining 11 compounds, AB05-AB08, AB13, and AB40-AB45 were 
not evaluated as the Osiris program could not recognize their cationic structures. 
 
An overall acceptable cLogP value below 5.0 was observed for 88% (n=30) of the 
compounds screened; such ccompounds are known to have a good probability of 
cellular absorption (http://www.organic-chemistry.org/prog/peo/cLogP.html accessed 
07-09-2011). Approximately 79% (n=27) of compounds were predicted to be 
lipophilic while the remaining were predicted to be hydrophilic (high LogP values 
represent low hydrophilicities; http://www.organic-
chemistry.org/prog/peo/cLogP.html accessed 07-09-2011). Most of the gold 
compounds were predicted to have LogS values below -4 (which means that 
compounds were predicted to have low aqueous solubility; http://www.organic-
chemistry.org/prog/peo/cLogP.html accessed 07-09-2011) with the exception of 
AB10 and AB11. Low solubility is associated with poor cellular absorption and 
distribution characteristics. 
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The compounds in Series 1 were predicted to consist of fragments associated with 
mutagenic, tumourigenic and reproductive effects as shown in Table 3.1. Series 2 & 3 
was predicted to consist of fragments known to induce tumourigenic and reproductive 
effects, with only AB10 and AB11 thought to be irritants. In Series 4, AB14 was 
associated with mutagenic and irritant effects, while AB16 and AB17 were only 
considered irritants. AB18 and AB19 consisted of fragments known to induce 
mutagenic effects. AB20 to AB34 and AB36 were all predicted to consist of 
fragments associated with irritant effects with AB22 containing an additional 
mutagenic fragment. Compound AB39 from Series 5 was associated with irritant 
effects. 
 
Assessment of the compounds by Osiris Property Explorer indicated that the presence 
of ethyl acetate and phenylphosphine fragments contributed to the irritancy while 
pyrazoles were suggested to contribute to mutagenecity. The structures of ethyl 
acetate, phenylphosphine and pyrazoles are shown in Figure 3.1.  
 
Overall, 31 of the 34 gold compounds screened showed low drug scores with the 
exception of AB10, AB11 and AB17 which exhibited intermediate drug likeness 
scores.  
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Table 3.1: Osiris Property Explorer assessment of 34 synthetic gold compounds. 
 
Compound cLogP LogS M.W. 
g/mol 
Drug-
Likeness 
Muta-
genic 
Tumor-
igenic 
Irritant R.E. Drug 
score 
Raltegravir  -1.05 -1.18 444.0 5.95     0.81 
Series 1 
AB01 4.01 -10.84 1105.39 -33.63     0.09 
AB02 4.01 -10.84 1105.39 -31.52     0.09 
AB03 3.72 -10.00 1135.56 -25.83     0.09 
AB04 3.11 -10,72 1207.58 -27.80     0.09 
Series 2 
AB09 3.65 -7.09 673.34 -31.38  -   0.09 
AB10 3.44 -3.28 518.22 1.15  -   0.43 
AB11 3.81 -2.05 511.35 0.33  -   0.50 
Series 3 
AB12 1.13 -5.74 500.67 -29.76     0.29 
Series 4 
AB14 4.87 -10.49 982.61 -42.954     0.061 
AB15 -0.87 -7.7 678.21 -11.43     0.15 
AB16 5.91 -12.8 968.57 -39.7     0.06 
AB17 -0.25 -4.11 340.11 -6.22     0.4 
AB18 3.01 -9.403 926.50 -37.55     0.08 
AB19 -2.373 -5.104 678.21 -12.409     0.162 
AB20 1.853 -9.381 928.47 -37.55     0.10 
AB21 4.401 -10.214 970.0 -40.264     0.07 
AB22 4.015 -10.967 970.55 -40.624     0.07 
AB23 3.47 -6.26 970.55 -47.67     0.16 
AB24 3.25 -10.19 982.61 -40.62     0.098 
AB25 5.72 -11.58 982.61 -42.03     0.07 
AB26 3.06 -8.95 984.58 -42.95     0.1 
AB27 3.83 -9.73 984.58 -42.03     0.07 
AB28 4.77 -14.75 1044.60 -37.69     0.08 
AB29 6.16 -15.56 1086.66 -42.95     0.06 
AB30 5.7 -15.29 1072.66 -40.62     0.07 
AB31 -0.36 -5.35 392.00 -7.28     0.31 
AB32 -1.08 -10.18 825.44 -12.4     0.13 
AB33 3.96 -7.66 1018.00 -15.8     0.17 
AB34 4.28 -15.95 1072.66 -45.14     0.08 
AB35 -1.56 -11.38 810.00 -19.92     0.13 
AB36 3.82 -15.68 1004.00 -45.02     0.09 
AB37 3.71 -8.27 420.00 -23.2     0.16 
AB38 -0.6 -5.95 407.00 -14.82     0.28 
Series 5 
AB39 3.68 -9.73 1018.00 -45.53     0.09 
AZT. Azidothymidine █ No negative effect. █ Negative effect.  R.E. Reproducible effects 
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Figure 3.1: Fragments identified through Osiris Property Explorer present in the gold compounds 
assessed known to induce cytotoxicity. 
 
 
3.1.2. Lipinski’s Ro5 of synthetic compounds  
 
All 45 compounds screened met the following Lipinski’s Ro5 requirements: they 
consisted of hydrogen bond acceptors less than five and had less than ten hydrogen 
donors (Table 3.2). Most of the gold compounds screened had high molecular weights 
(MW) i.e. MW>500g/mol with the exception of AB17, AB31 and AB38. Compounds 
screened met the required solubility criteria i.e. partition co-efficiencies were 
predominantly less than five with the exception of AB16, AB25, AB29 and AB30. 
Only AB17, AB31, and AB38, had good Lipinski’s Ro5 scores (4/4) whereas the rest 
of the compounds exhibited intermediate scores (3/4 or 2/3). Some of the gold 
compounds namely AB39-AB45, were not screened for cLogP because partitioning 
co-efficiencies could not be obtained from the Osiris Property Explorer; therefore 
these compounds were assessed using only the information that could be accumulated 
on them. The Lipinski’s Ro5 scores are represented as percentages in Figure 3.2. 
Overall, only 7.3% (n=3) of the gold compounds investigated are possible orally 
bioavailable drug candidates by the Lipinski’s Ro5. A good portion (86%, n=39) of 
compounds were predicted to exhibit intermediate oral bioavailability while the 
remaining compounds showed low Lipinski’s Ro5 scores. 
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Table 3.2: Evaluation of 45 synthetic gold compounds using the Lipinski’s Ro5. 
Compound Rule 1 Rule 2 Rule 3 Rule 4 Score 
Raltegravir √ √ √ √ 4/4 
Series 1 
AB01 √ √ х √ 3/4 
AB02 √ √ х √ 3/4 
AB03 √ √ х √ 3/4 
AB04 √ √ х √ 3/4 
Series 2 
AB05 √ √ х √ 3/4 
AB06 √ √ х √ 3/4 
AB07 √ √ х √ 3/4 
AB08 √ √ х √ 3/4 
AB09 √ √ х √ 3/4 
AB10 √ √ х √ 3/4 
AB11 √ √ х √ 3/4 
Series 3 
AB12 √ √ х √ 3/4 
AB13 √ √ х √ 3/4 
Series 4 
AB14 √ √ x √ 3/4 
AB15 √ √ x √ 3/4 
AB16 √ √ x x 2/4 
AB17 √ √ √ √ 4/4 
AB18 √ √ x √ 3/4 
AB19 √ √ x √ 3/4 
AB20 √ √ x √ 3/4 
AB21 √ √ x √ 3/4 
AB22 √ √ x √ 3/4 
AB23 √ √ x √ 3/4 
AB24 √ √ x √ 3/4 
AB25 √ √ x х 2/4 
AB26 √ √ x √ 3/4 
AB27 √ √ x √ 3/4 
AB28 √ √ x √ 3/4 
AB29 √ √ x x 2/4 
AB30 √ √ x x 2/4 
AB31 √ √ √ √ 4/4 
AB32 √ √ x √ 3/4 
AB33 √ √ x √ 3/4 
AB34 √ √ x √ 3/4 
AB35 √ √ x √ 3/4 
AB36 √ √ x √ 3/4 
AB37 √ √ x √ 3/4 
AB38 √ √ √ √ 4/4 
Series 5 
AB39 √ √ x ND 2/3 
AB40 √ √ x ND 2/3 
AB41 √ √ x ND 2/3 
AB42 √ √ x ND 2/3 
AB43 √ √ x ND 2/3 
AB44 √ √ x ND 2/3 
AB45 √ √ x ND 2/3 
Rule 1: Not more than 5 hydrogen bond acceptors.  Rule 2: Not more than 10 hydrogen donors. Rule 3: 
A molecular weight under 500g/mol.  Rule 4. A partition coefficient log P less than 5.  X: Does not 
adhere to rule. √: Adheres to rule. ND: Not done. AZT. Azidothymidine. Score: Lipinski’s Ro5 Score 
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Figure 3.2: Overall Lipinski’s Ro5 scores of the 45 investigated gold compounds. 
 
Based on the combined results from the Osiris Property Explorer and Lipinski’s Ro5, 
gold compounds AB10, AB11, AB17, AB31 and AB38 are theoretically good drug 
candidates. 
 
 
3.2. Aqueous solubility of synthetic gold compounds 
 
To determine the aqueous solubility of each synthetic gold compound, a standard 
curve for each compound was first obtained. Figure 3.3 shows the representative 
standard curve for which the chloramphenicol control is the test compound. From the 
standard curve of each synthetic gold compound (results not shown), aqueous 
solubility was determined. The compounds demonstrated varied aqueous solubility as 
shown in Table 3.3. The synthetic gold compounds with a value of >400µM were 
considered soluble. Overall, compounds AB17, AB31, AB32, and AB37 were 
observed to be soluble at concentrations between 400µM and 500µM in aqueous 
medium, while AB13, AB15, AB19, AB35, AB36 and AB38 were soluble at 
concentrations above 500µM but below 800µM. The overall solubility levels for the 
45 synthetic gold compounds are depicted graphically in Figure 3.4. It was observed 
that 36% (n= 16) of the gold compounds were soluble in aqueous media, 40% (n=18) 
showed poor solubility and approximately 24% were observed to exhibit moderate 
aqueous solubility. The compounds AB01-AB04 exhibited low/no solubility and were 
observed to precipitate out of solution. The compounds in Series 5 (AB39-AB45) 
were observed to be moderately soluble to soluble but the assay results were not 
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reproducible for these 7 compounds; which mean that the compounds precipitated out 
of solution at varying rates.  
 
 
Figure 3.3: The representative standard curve of aqueous solubility in which chloramphenicol was the 
test compound.  
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Table 3.3: Aqueous solubility of the 45 synthetic gold compounds and the 
chloramphenicol control compound. 
 
Compound Absorbance 
(nm) 
Slope(M) R2 Solubility (µM)/S ±  
Std dev 
Chloramphenicol 290 0.003917 0.986 406.635 ± 59.746 
Series 1 
AB01 NS NS NS *NS 
AB02 NS NS NS *NS  
AB03 NS NS NS *NS 
AB04 NS NS NS *NS  
Series 2 
AB05 320 0.006 0.898 323.437 ± 16.026 
AB06 320 0.0039 0.922 266.025 ± 13.042 
AB07 320 0.8058 0.894 4.884 ± 0.006 
AB08 320 0.0064 0.917 306.884 ± 49.934 
AB09 320 0.006 0.863 332.586 ± 18.480 
AB10 320 0.0035 0.971 394.583 ± 2.875 
AB11 320 0.0063 0.961 283.283 ± 0.773 
Series 3 
AB12 270 0.0031 0.993 195.766 ± 16.478 
AB13 270 0.0019 0.983 526.644 ± 0.909 
Series 4 
AB14 290 0.0018 0.944 62.538 ± 3.002 
AB15 290 0.0007 0.934 814.285 ± 6.860 
AB16 290 0.0011 0.888 71.875 ± 6.625 
AB17 290 0.0002 0.964 430.208 ± 13.906 
AB18 290 0.0046 0.962 24.818 ± 3.725 
AB19 290 0.002 0.994 769.583 ± 8.188 
AB20 290 0.0022 0.991 39.867 ± 6.923 
AB21 270 0.0006 0.881 147.916 ± 40.991 
AB22 270 0.0009 0.897 99.845 ± 67.917 
AB23 270 0.0009 0.943 95.370 ± 24.277 
AB24 270 0.0008 0.942 122.916 ± 18.541 
AB25 270 0.0013 0.941 65.865 ± 96.873 
AB26 270 0.0006 0.860 238.425 ± 3.076 
AB27 270 0.0009 0.997 103.472 ± 10.196 
AB28 270 0.0063 0.945 362.946 ± 33.816 
AB29 270 0.0054 0.999 219.444 ± 25.782 
AB30 270 0.0056 0.996 260.732 ± 42.538 
AB31 270 0.0049 0.997 426.934 ± 43.694 
AB32 270 0.0064 0.962 482.541 ± 23.845 
AB33 270 0.0063 0.995 103.670 ± 2.273 
AB34 270 0.0031 0.947 141.061 ± 34.624 
AB35 270 0.0063 0.911 650.948 ± 150.193 
AB36 270 0.0065 0.734 575.144 ± 34.527 
AB37 270 0.0013 0.924 493.269 ± 11.576 
AB38 270 0.0046 0.990 524.184 ± 1.408 
Series 5 
AB39 270 0.0006 0.910 241.319 ± 44.676 
AB40 270 0.0013 0.999 534.054 ± 49.609 
AB41 270 0.0012 0.996 563.454 ± 269. 
AB42 270 0.006 0.999 525.781 ± 793.138 
AB43 270 0.0017 0.999 531.433 ± 14.295 
AB44 270 0.003 0.999 522.222 ± 39.682 
AB45 270 2.00E-05 0.815 4513.889 ± 32.632 
*NS=Not soluble 
 Chapter 3 
 57 
 
 
 
Figure 3.4:  Proportion of the 45 synthetic gold compounds exhibiting aqueous solubility. 
 
 
3.3. Measurement of cell cytotoxicity 
 
The CC50 for the synthetic gold compounds were determined in PM1 cell lines for all 
compounds and PBMCs (AB05-AB11) using auranofin (Figure 3.5) and AZT as the 
respective controls. The cytotoxicity was determined and the CC50 values exhibited 
varying cytotoxicity among test agents as summarised in Table 3.4.  
 
The cytotoxicity in PBMCs for compounds AB05-AB11 was comparable to that of 
the PM1 cell line, with the exception of AB10 and AB11. The cytotoxicity of AB10 
in the PBMCs (CC50=56.5µM) was approximately half that observed in the PM1 cell 
line (CC50 = 107.412 ± 4.099µM); and AB11 was approximately 4 fold more 
cytotoxic in PBMCs.  
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Figure 3.5: A representative graph that demonstrates the relationship between PM1 cell viability and 
auranofin concentration. The auranofin concentration required to reduce cell viability by 50% was 
determined to be less than 1.652. The Y-axis represents optical density at a wavelength of 490nm. The 
X-axis represents the Log values of varying compound concentrations.   
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Table 3.4: Evaluation of gold compounds cytotoxicity in PM1 cells and PBMCs. 
 
 
Compound CC50 (µM) ± Std dev CC50 (µM) ± Std dev 
 PM1 cell line PBMCs 
Control compound <1.562 (Auranofin)a >1000nm (AZT)b 
Series 1 
AB01 10.741 ± 2.143 х10-16 - 
AB02  >100 - 
AB03 >100 - 
AB04 >100 - 
Series 2 
AB05 49.403 ± 0.130 40.6 
AB06 11.276 ± 3.467х10-16 6.28 
AB07 22.771 ± 1.515х10-15 18.7 
AB08 3.423 ± 8.485х10-18 2.94 
AB09 3.054 ± 0.275 2.45 
AB10 107.412 ± 4.099 56.5 
AB11 33.847 ± 6.201 8.30 
Series 3 
AB12 9.655 ± 7.130х10-15 - 
AB13 0.994 ± 1.250х10-17 - 
Series 4 
AB14 <1.5625 - 
AB15 72.8 ± 9.298 - 
AB16 <1.5625 - 
AB17 4.625 ± 1.661 - 
AB18 <1.5625 - 
AB19 <1.5625 - 
AB20 <1.5625 - 
AB21 1.590 ± 0.551 - 
AB22 1.250 ± 0.070 - 
AB23 <1.5625 - 
AB24 <1.5625 - 
AB25 3.100 ± 0.565 - 
AB26 <1.5625 - 
AB27 2.366 ± 0.550 - 
AB28 2.125 ± 0.671 - 
AB29 <1.5625 - 
AB30 <1.5625 - 
AB31 3.05 ± 0.777 - 
AB32 34.140 ± 3.592 - 
AB33 1.780 ± 0.254 - 
AB34 <1.5625 - 
AB35 <1.5625 - 
AB36 2.800 ± 0.144 - 
AB37 <1.5625 - 
AB38 <1.5625 - 
Series 5 
AB39 2.190 ± 4.444х10-16 - 
AB40 116.493 ± 4.177х10-15 - 
AB41 48.827 ± 1.221х10-15 - 
AB42 31.855 ± 3.177х10-15 - 
AB43 54.697 ± 4.233х10-15 - 
AB44 31.125 - 
AB45 >100 - 
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In general 64.4% (n= 29) of gold compounds were observed to be cytotoxic in the 
PM1 cell line (CC50 values ≤10µM). Approximately 22.2% (n=10) of test compounds 
showed moderate cytotoxicity (CC50 values between 10µM and 100µM) while 13.3% 
(n=6) exhibited low cytotoxicity (CC50 values > 100µM). 
 
3.4. Direct enzyme activity 
 
In order to establish a mechanism of HIV-1 inhibition, gold compounds were 
screened for inhibition of the integrase enzyme and the reverse transcriptase enzyme. 
 
3.4.1. Direct HIV-1 integrase inhibition 
 
At a concentration of 10µM, the 45 synthetic gold compounds were mostly observed 
to exhibit low levels of integrase inhibition, as shown in Table 3.5. AB04 and AB39 
exhibited IN inhibition of approximately 52.8% and the rest of the compounds did not 
reach the cut-off of 50% inhibition at 10µM. The remaining compounds demonstrated 
negligible IN inhibition. Overall, strand transfer inhibition assays showed that only 
two of the gold compounds inhibit IN mediated strand transfer, meaning that at 10µM 
these gold compounds reduce the activity of IN from 100% to approximately 48%. 
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Table 3.5: The direct inhibition of HIV-1 strand transfer activity by each of the 45 
synthetic gold compounds. 
 
Compound 10µM Percent inhibition (%) 
Chicoric Acid 98.759 
Series 1 
AB01 NI 
AB02 NI 
AB03 NI 
AB04 52.800 
Series 2 
AB05 NI 
AB06 NI 
AB07 NI 
AB08 NI 
AB09 NI 
AB10 NI 
AB11 NI 
Series 3 
AB12 NI 
AB13 NI 
Series 4 
AB14 43.294 ± 3.580 
AB15 32.337 ± 2.567 
AB16 NI 
AB17 41.183 ± 2.089 
AB18 NI 
AB19 NI 
AB20 18.373 ± 4.157 
AB21 NI 
AB22 19.376 ± 5.522 
AB23 NI 
AB24 28.405 ± 0.596 
AB25 24.920 ± 1.635 
AB26 NI 
AB27 NI 
AB28 27.771 ± 2.630 
AB29 40.496 ± 0.085 
AB30 20.863 ± 1.484 
AB31 30.517 ± 1.483 
AB32 22.333 ± 9.487 
AB33 27.032 ± 8.195 
AB34 NI 
AB35 44.852 ± 0.479 
AB36 36.536 ± 6.445 
AB37 NI 
AB38 NI 
Series 5 
AB39 52.842 
AB40 NI 
AB41 NI 
AB42 NI 
AB43 NI 
AB44 NI 
AB45 NI 
NI - no inhibition of HIV-1 integrase strand transfer 
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3.4.2. Direct RT assay 
 
All 45 gold compounds were successfully tested for direct HIV-1 RT inhibition at a 
concentration of 10µM. Depending on their potency they were subsequently tested at 
1µM, followed by 0.5µM and 0.1µM (Table 3.6). Overall, 12 of the 45 compounds 
exhibited direct inhibition of RT activity at concentrations above 50% at a 10µM 
concentration. In addition, the IC50 values of 10 of 11 compounds which showed 
direct RT activity at the lower concentrations tested was determined, and ranged from 
0.46 to 50.39µM.   
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Table 3.6: Gold compounds HIV-1 RT direct inhibition. 
 
Compound 10µM % 
inhibition  
1µM % 
inhibition  
0.5µM % 
inhibition  
0.1µM % 
inhibition  
IC50a(µM)± Std 
dev 
AZT-tp 98.346  - - - - 
Neviripine 99.676 - - - - 
Series 1 
AB01 16.302 - - - - 
AB02 15.210 - - - - 
AB03 14.117 - - - - 
AB04 9.803 - - - - 
Series 2 
*AB05 75.966 78.033 43.968 14.405 0.502 ± 0.018 
*AB06 72.212 76.761 44.446 13.716 0.461 ± 0.053 
*AB07 74.677 79.207 52.036 14.388 0.503 ± 0.042 
*AB08 76.526 86.839 46.224 21.726 0.660 ± 0.000 
*AB09 77.815 30.870 - - 1.381 ± 0.220 
*AB10 75.686 52.886 - - 1.054 ± 0.001 
*AB11 73.557 44.863 - - 8.796 ± 0.016 
Series 3 
AB12 9.747 - - - - 
AB13 18.151 - - - - 
Series 4 
AB14 <0 - - - - 
AB15 <0 - - - - 
AB16 <0 - - - - 
AB17 14.864 - - - - 
AB18 11.261 - - - - 
AB19 14.513 - - - - 
AB20 4.391 - - - - 
AB21 4.902 - - - - 
AB22 <0 - - - - 
AB23 <0 - - - - 
AB24 <0 - - - - 
AB25 <0 - - - - 
AB26 20.253 - - - - 
AB27 22.626 - - - - 
AB28 14.100 - - - - 
AB29 19.932 - - - - 
AB30 9.117 - - - - 
AB31 10.534 - - - - 
AB32 13.770 - - - - 
AB33 9.940 - - - - 
AB34 18.694 - - - - 
AB35 74.393 7.809 1.756 - - 
AB36 15.863 - - - - 
AB37 <0 - - - - 
AB38 11.711 - - - - 
Series 5 
*AB39 70.726 40.361 - - 10.900 ± 1.979 
AB40 48.446 24.698 - - - 
AB41 67.924 37.148 - - 50.390 ± 0.636 
*AB42 60.266 33.935 - - 13.350 ± -0.777 
AB43 51.664 40.736 - - - 
AB44 17.230 - - - - 
AB45 <4.533 - - - - 
*Compounds identified to exhibit considerable inhibition of HIV-1 RT. AZT-tp:3´-Azido-3´- 
Deoxythymidine-5´- Triphosphate 
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3.4.2.1. Effect of 10% FCS on direct HIV-1 RT inhibition  
 
The four synthetic gold(III) compounds with good IC50 values in Series 2 (AB05-
AB08; Table 3.6) were retested at the 10µM concentration in the direct RT assay in 
the presence of 10% FCS, and percentage inhibition values were compared (Figure 
3.6). The presence of foetal calf serum was shown to reduce the anti-HIV-1 RT 
activity of compounds AB05-AB08 significantly (p value <0.05). The percentage 
inhibitions were reduced from 75.9 to 17.9%, 72.20 to 20%, 71.6 to 36.6% and 76.5 
to 44.1% for AB05, AB06, AB07 and AB08, respectively. 
 
 
Figure 3.6: Effect of 10% foetal calf serum on the ability of four selected synthetic gold(III) 
compounds (10µM; Series 2) to directly inhibit HIV-1 RT activity. The p-values which represents 
significance in changes were obtained using the Student t-test which compared the original percentage 
inhibitions of the compounds with those in assay modified with of 10% FCS. a The fold difference in 
percentage inhibition in the assay following introduction of 10% FCS.  
  
3.4.2.2. Effect of 4.5mg/ml HSA on direct HIV-1 RT inhibition 
The presence of 4.5mg/ml HSA in the direct HIV-1 RT assay reduced the potency of 
AB05, AB06, AB07 and AB08 across the range of concentrations tested, and thus 
increased IC50 values significantly (p<0.05) as shown in Table 3.7. 
 
Table 3.7: The effect of 4.5mg/ml HSA on selected Series 2 gold(III) compounds 
direct HIV-1 RT inhibition 
 IC50(µM) in the 
absence of HSA 
IC50(µM) in the 
presence of  HSA 
P-valuea FCIC50b 
AB05 0.502±0.018 15.941±0.439 0.0003 31.754 
AB06 0.461±0.053 16.157± 6.610 0.0027 35.047 
AB07 0.503±0.042 9.575 ±1.570 0.009 19.035 
AB08 0.660±0.000 5.328 ± 0.963 0.004 8.072 
aThe p-value was obtained using the Student t-test which compared the compound original IC50 values 
shown in Table 3.6 and those obtained in the 10% HSA (4.5mg/ml) reaction.bThe FCIC50 demonstrates 
the fold difference in IC50’s.  
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3.4.2.3. Direct HIV-1 RT inhibition of HIV-1HXB2 reverse transcriptase 
(p66>Q/p51) mutant which lacks RNase H activity 
 
The four selected gold(III) compounds (AB05-AB08; Series 2) were evaluated for 
inhibition of a mutant p66 at a concentration of 10µM.  Residual RT activity (as 
measured by A405) in the presence of each of the four compounds is shown in Figure 
3.7. As shown earlier, these values were used to determine the percentage direct RT 
inhibition for each compound (reported in the Table within Figure 3.7). The 
compounds exhibited exceptional inhibition of the p66 RT subunit; with percentage 
inhibitions from a low of 97.124% (AB08) to 99.295% (AB05).     
 
Figure 3.7: Direct RT inhibition of the HIV-1HXB2 reverse transcriptase (p66>Q/p51) mutant which 
lacks RNaseH activity. The test compounds exhibited inhibitions that ranged from 97.125% (AB08) to 
99.295% (AB05). The positive control contains the HIV-1 RT without inhibitors. The negative control 
does not contain HIV-1 RT.  
 
 
3.4.2.4. Direct HIV-1 RT Inhibition of a 3TC/Lamivudine resistant 
mutant  
 
The inhibition of the 3TC/lamivudine resistant mutant HIV-1 RT by the four selected 
Series 2 compounds was determined at a 10µM concentration. Residual RT activity 
(as measured by A405) in the presence of each of the four compounds is shown in 
Figure 3.8. These values were used to determine the percentage direct RT inhibition 
for each compound (reported in the Table within Figure 3.8).  
 Chapter 3 
 66 
 
Figure 3.8: Direct RT inhibition of the HIV-1HXB2 reverse transcriptase/M184V mutant which is 
known to be resistant to 3TC/lamivudine by 10µM gold-based compounds. . The test compounds 
exhibited inhibitions in the ranges 65.351% (AB08) to 75.826% (AB05). The positive control contains 
the HIV-1 RT and reaction mixture. The negative control contains the reaction mixture. 
 
 
3.5. Antiviral activity in PBMCs 
 
Series 2 synthetic gold(III) compounds showed low/no cytotoxicity (Table 3.4) and 
direct RT inhibition with IC50 values below 10µM (Table 3.6), and were therefore 
selected for in vitro phenotypic inhibition assays. The results from the testing of 
compounds AB05 to AB11 against growth of HIV-1 subtype B isolates BaL (CCR5-
utilizing) and NL4-3 (CXCR4-utilizing) in PBMCs are summarised in Table 3.7. 
 
Acceptable IC50 values at a range 0.41µM to 40.8µM were observed. Antiviral 
activity observed was isolate dependent. HIV-1BaL was more easily inhibited than 
HIV-1NL4-3 by all the synthetic gold compounds, but more resistant to inhibition by 
AZT.  However, the compounds exhibit cytotoxicity at CC50 concentrations that are 
slightly higher than the compounds IC50, resulting in low SI values. These results 
indicate that the compounds in their current form are poor drug candidates to continue 
to the preclinical development phase. The cytotoxicity and antiviral graph curves 
(results not shown) were also observed to be paralleled which was an indication of 
loss of viral replication due to cell death by the gold compounds.  
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Table 3.8: Inhibition of HIV-1 by gold(III) compounds (Series 2) in PBMCs. 
Compounds HIV-1 
Isolate 
IC50(µM) *CC50(µM) Selective Index 
(SI)a 
AB05 Ba-L 14.1 40.6 
 
2.87 
NL4-3 37.2 1.09 
AB06 Ba-L 3.66 6.28 1.71 
NL4-3 4.43 1.42 
AB07 Ba-L 8.22 18.7 
 
2.27 
NL4-3 13.0 1.43 
AB08 Ba-L 1.83 2.94 1.61 
NL4-3 3.15 <1.00 
AB09 Ba-L 0.41 2.45 
 
5.95 
NL4-3 1.12 2.19 
AB10 Ba-L 23.5 56.5 2.41 
NL4-3 40.8 1.38 
AB11 Ba-L 1.80 8.30 4.60 
NL4-3 7.86 1.06 
AZT Ba-L 2.34nM >1000nM >427 
NL4-3 1.30nM >834 
aThe SI was determined by division of the CC50 with the IC50 values obtained. *PBMC cytotoxicity 
data obtained from Table 3.4 
 
3.6. 1H NMR analysis of synthetic gold compound interactions with HSA 
 
The saturation transfer differences (STD) were obtained for compounds AB05-AB11. 
Figure 3.9 depicts the interaction of each compound with HSA, as determined through 
subtraction of spectral intensities of ligands before and after binding. Overall, all 
compounds, except AB07 and AB09, showed STD peaks which means that these 
compounds interact with the protein. For instance, AB05 peaks were observed at 8.0-
9.0ppm, AB06 and AB08 peaks where observed between 2.0-1.0ppm, AB10 and 
AB11 showed STD peaks between 3.0-2ppm and 3-1ppm respectively. The lack of 
STD signal of AB07 and AB09 could be attributed to two factors: the lack of binding 
or alternatively high affinity binding (false negative). 
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Figure 3.9: STD spectra of theAB05-AB11 Series of compounds to HSA (1:0.01mM) in 5% DMSO-
d6 deuterated  PBS, using auranofin as a reference. The black circles depict STD peaks which 
represent interaction of protein and compound. 
 
 
Competitive binding assays were then carried out using compound AB05 to establish 
where on the serum protein HSA the compounds bind. Auranofin was used as a 
control as it is known to bind the Cys34 on the surface of HSA (Figure 3.10). Figure 
3.10 shows the three signals obtained from the STD technique for auranofin with 
HSA, and auranofin, AB05 and HSA with (a) unsaturated protein, (b) protein 
saturation (with water suppression), and (c) the difference in signals between a and b, 
which is a result of a binding ligand that exhibit changes in the intensities of signal 
subsequent to interaction with a saturated protein. STD peaks observed at 2-1ppm are 
a demonstration that AB05 displaces auranofin therefore implies a common binding 
site for both compounds. 
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Figure 3.10: Auranofin binding to HSA (1: 0.01 mM) with 5% DMSO-d6 in PBS (D2O). The circled 
peaks are the highlighted STD which represents interaction of protein and compound. (a) unsaturated 
protein, (b) protein saturation (with water suppression), and (c) the difference in signals between a and 
b. 
 
3.7. Compound stability in 10% RPMI complete media over time 
 
STD NMR was also used to evaluate the compounds AB05-AB08 stability in 
biological media. AB05 was observed to lose signal intensity at 8.5-9.0ppm and at 
~7.5ppm and 8ppm (Figure 3.11). AB06 STD was observed to lose intensity at 
~1.4ppm over 72hours. AB07 showed no changes in STD signal until the 72nd hour 
when a signal was observed at ~8.5ppm, and AB08 exhibited loss of signal intensity 
at approximately 1.4ppm. Loss of signal intensities shows loss in chemical structure 
of the gold compounds due to interactions with serum proteins in 10% FCS. This 
implies the compounds are not stable in biological media.  
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Figure 3.11: Stability of AB05-AB08 in 10% complete RPMI media at 37°C using STD NMR. AB05 
stability was read after 0.5h, 1.5h, 3h and 24h; while compounds AB06-AB08 were read after 0.5h, 
1.5h, 3h, 7h and 72h. The black circles depict STD peaks which represent the stability of the 
compounds at the given times. 
  
 
3.8. Summary of theoretical and experimental data obtained for the 45 gold 
compounds evaluated in this study  
 
Table 3.9 below summarises all quantitative data obtained in this study. This excludes 
the NMR results since that work was not analysed numerically.  
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Table 3. 9: Summary of all theoretical and experimental data obtained for the 45 gold compounds evaluated in this study. 
Compound Osiris 
Property 
explorer score 
Lipinki’s 
Ro5 score 
Solubility Cytotoxicity in 
PM1 cells 
Cytotoxicity 
in PBMCs 
IN strand 
transfer 
inhibition 
RT direct 
inhibition 
(10uM) 
RT direct 
inhibition 
IC50 
Antiviral 
activity 
Ba-L (SI) 
 
Antiviral 
activity 
NL4-3 (SI) 
AZT - - - - >1000nM - - - 2.34(>427) 1.30(>834) 
Ral 0.81 4/4 - - - - - - - - 
Series 1 
AB01 0.09 3/4 *NS 10.741  - NI 16.302 - - - 
AB02 0.09 3/4 *NS  >100 - NI 15.210 - - - 
AB03 0.09 3/4 *NS >100 - NI 14.117 - - - 
AB04 0.09 3/4 *NS  >100 - 52.800 9.803 - - - 
Series 2 
AB05 - 3/4 323.437  49.403  40.6 NI 75.966 0.502  14.1(2.87) 37.2 (1.09)  
AB06 - 3/4 266.025  11.276  6.28 NI 72.212 0.461 3.66 (1.71) 4.43 (1.42) 
AB07 - 3/4 4.884 22.771  18.7 NI 74.677 0.503  8.22 (2.27) 13.0 (1.43) 
AB08 - 3/4 306.884 3.423  2.94 NI 76.526 0.660  1.83 (1.61) 3.15 (<1.00) 
AB09 0.09 3/4 332.586  3.054  2.45 NI 77.815 1.381  0.41 (5.95) 1.12 (2.19) 
AB10 0.43 3/4 394.583  107.412  56.5 NI 75.686 1.054  23.5 (2.41) 40.8 (1.38) 
AB11 0.50 3/4 283.283  33.847  8.30 NI 73.557 8.796  1.80 (4.60) 7.86 (1.06) 
Series 3 
AB12 0.29 3/4 195.766  9.655  - NI 9.747 - - - 
AB13 - 3/4 526.644  0.994  - NI 18.151 - - - 
Series 4 
AB14 0.061 3/4 62.538  <1.5625 - 43.294  <0 - - - 
AB15 0.15 3/4 814.285 72.8  - 32.337  <0 - - - 
AB16 0.06 3/4 71.875  <1.5625 - NI <0 - - - 
AB17 0.4 4/4 430.208 4.625  - 41.183  14.864 - - - 
AB18 0.08 3/4 24.818  <1.5625 - NI 11.261 - - - 
AB19 0.162 3/4 769.583  <1.5625 - NI 14.513 - - - 
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Compound Osiris 
Property 
explorer drug 
score 
Lipinki’s 
Ro5 score 
Solubility Cytotoxicity in 
PM1 cells 
Cytotoxicity 
in PBMCs 
IN strand 
transfer 
inhibition 
RT direct 
inhibition 
(10uM) 
RT direct 
inhibition 
IC50 
Antiviral 
activity 
BaL 
 
Antiviral 
activity 
NL4-3 
 
AB20 0.10 3/4 39.867  <1.5625 - 18.373  4.391 - - - 
AB21 0.07 3/4 147.916  1.590  - NI 4.902 - - - 
AB22 0.07 3/4 99.845  1.250  - 19.376  <0 - - - 
AB23 0.16 3/4 95.370  <1.5625 - NI <0 - - - 
AB24 0.098 3/4 122.916  <1.5625 - 28.405  <0 - - - 
AB25 0.07 2/3 65.865 3.100 ± - 24.920  <0 - - - 
AB26 0.1 3/4 238.425  <1.5625 - NI 20.253 - - - 
AB27 0.07 3/4 103.472 2.366  - NI 22.626 - - - 
AB28 0.08 3/4 362.946  2.125  - 27.771  14.100 - - - 
AB29 0.06 2/4 219.444  <1.5625 - 40.496  19.932 - - - 
AB30 0.07 2/4 260.732  <1.5625 - 20.863  9.117 - - - 
AB31 0.31 4/4 426.934  3.05  - 30.517  10.534 - - - 
AB32 0.13 3/4 482.541  34.140  - 22.333  13.770 - - - 
AB33 0.17 3/4 103.670  1.780  - 27.032  9.940 - - - 
AB34 0.08 3/4 141.061  <1.5625 - NI 18.694 - - - 
AB35 0.13 3/4 650.948  <1.5625 - 44.852  74.393 - - - 
AB36 0.09 3/4 575.144  2.800  - 36.536  15.863 - - - 
AB37 0.16 3/4 493.269  <1.5625 - NI <0 - - - 
AB38 0.28 4/4 524.184  <1.5625 - NI 11.711 - - - 
Series 5 
AB39 0.09 2/3 241.319  2.190  - 52.842 70.726 10.900  - - 
AB40 - 2/3 534.054  116.493  - NI 48.446 - - - 
AB41 - 2/3 563.454  48.827  - NI 67.924 50.390  - - 
AB42 - 2/3 525.781  31.855  - NI 60.266 13.350 - - 
AB43 - 2/3 531.433  54.697  - NI 51.664 - - - 
AB44 - 2/3 522.222  31.125 - NI 17.230 - - - 
AB45 - 2/3 4513.889  >100 - NI <4.533 - - - 
█ Desired biological properties. 
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CHAPTER 4 
DISCUSSION 
 
 
The early stages of drug discovery have become progressively complex since the 
addition of development hurdles aimed at reducing the failure rate of candidate 
compounds further down the pipeline. These development hurdles include profiling of 
drug candidates using in vitro and in vivo techniques early in the development 
process; notably the evaluation of ADMET parameters which would typically require 
advanced preclinical studies. However, early drug candidate profiling which includes 
virtual analysis of compounds using in silico techniques is expected to result in 
synthesis of compounds with the highest drug-like properties (Gleeson, 2008). This 
study was designed to fit the currently adopted process of drug discovery and 
development by early profiling of 45 available gold compounds using theoretical 
screening and in vitro assessment techniques.  
 
Overall, theoretical screening identified six compounds AB10, AB11, AB17 (Osiris; 
Tables 3.1 and 3.9) and AB17, AB31 and AB38 (Lipinski Ro5; Tables 3.2 and 3.9) as 
best possible drug candidates. By contrast, in vitro phenotypic inhibition testing 
identified compounds AB05 to AB08 as best possible drug candidates (Tables 3.6 and 
3.9), albeit with high (AB08) to moderate cytotoxicity (Tables 3.4 and 3.9). The in 
vitro assessment of compounds HIV-1 inhibition, virtual screening of the compounds 
probability as drugs, and the evaluation of compounds ADMET properties such as 
solubility, plasma protein binding, stability and cytotoxicity allowed us to gather 
sufficient information to aid in the future rational design of gold-based HIV-1 
inhibitors, thus achieving the study objectives. 
 
4.1. Theoretical analysis  
 
Theoretical analysis of compounds involved the application of the Osiris Property 
Explorer (which predicted drug-like properties of the gold compounds) and Lipinski’s 
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Rule of Five (used to assess the probability of compounds as orally bioavailable 
drugs). These studies were carried out to gather information on the properties of the 
compounds to be tested such as drug-likeness and identify their shortcomings in order 
to aid future design of new gold based drug-like chemical entities.  
 
According to the Osiris Property Explorer, six parameters should be taken into 
consideration to generate hits for early stage drug discovery: toxicity risks, cLogP, 
aqueous solubility, molecular weight, drug-likeness and overall drug likeness score. A 
toxicity risk assessment identifies fragments known to induce mutagenicity, 
tumourigenicity, irritancy and reproductive effects. The cLogP is a measure of a 
compounds hydrophilicity or lipophilicity in which desired hydrophobicity is defined 
by low values (cLogP<5) for reasonable probability of absorption. Aqueous solubility 
(LogS) is also known to be associated with compound absorption, and a high aqueous 
solubility is desired for systematic transportation while some lipophilicity is necessary 
for cell membrane diffusion to reach target site of action (Jing et al., 2009).  
Optimizing compounds for efficacy within the drug development pipeline is almost 
always associated with increased MW, so it’s necessary to start with compounds that 
have low MW. High MW is also associated with decreased absorption and reduced 
potential of reaching the target site. Approximately 80% of all traded drugs have MW 
less than 450g/mol (http://www.organic-chemistry.org/prog/peo/mw.html accessed 
07-09-2011) therefore compounds with MW ≤450g/mol have a higher chance of 
success within the drug development pipeline than higher MW inhibitors. The 
fragment based drug-likeness sums up the fragments within a compound and a desired 
positive value represents drug-like properties frequently observed in traded drugs. The 
overall drug-likeness score sums all assessed parameters to judge a compound’s 
overall potential to qualify as a drug.  
 
In total 75.55% (n=34) of the gold compounds could be assessed using the Osiris 
Property Explorer. The remainder contain cationic structures that the Osiris Property 
Explorer could not account for during analysis. Overall the compounds were not drug-
like and the Osiris scores were low. Of the compounds screened 21% (n=7) were 
predicted as non-toxic while the remaining gold compounds were considered toxic. 
The predicted toxicity in Series 1 and AB12 (Series 3) was associated with fragments 
such as ethyl acetate/phenylphosphines and pyrazoles which are considered tumour 
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inducing mutagens and irritants respectively (illustrated in Figure 3.1). Therefore 
future rational design of gold-based anti-HIV compounds should minimize the use of 
these fragments to circumvent their toxic effects. The gold compounds were predicted 
to be mostly lipophilic with 9% (n=3) of them predicted to have cLogP values greater 
than five which meant they were highly lipophilic. This lipophilicity suggests these 
compounds would be less soluble in aqueous medium. The high lipophilicity further 
predicts low permeability through lipophilic cell membranes (Kellogg et al., 2005). 
Approximately 80% of FDA approved drugs have a LogS value greater than -4 (Osiris 
Property Explorer, http://www.organic-chemistry.org/prog/peo/logS.html accessed 
07-09-2011) and only 6% of the gold compounds tested in this study were predicted 
to fall within this desired solubility range. This implies that rational drug design of 
future gold compounds should use fragments associated with aqueous solubility 
specifically. In addition, 80% of the FDA approved drugs have a MW less than 
450g/mol (Osiris Property Explorer) whereas only 12% of the gold compounds had 
MW within the desired range. Reduction of molecular weights would require 
identification of chemical structure involved in inhibition and thereafter modifications 
can be made. However, this may not be feasible as the gold element itself is large 
(196.97g/mol) which then adds to the existing MW of the compounds; as a result gold 
compounds will inherently be bulky. Another parameter that led to reduced drug-
likeness (overall drug-likeness< 0.5) is the gold element within chemical structures 
since only a few metal based drugs are traded and are not likely to be part of the drug-
likeness reference database.  
 
The Lipinski’s Rule of Five predicts good oral absorption and bioavailability when 
compounds consist of hydrogen bond (H-bond) donors less than five, H-bond 
acceptors less than ten, compound MW is less than 500g/mol and LogP is less than 
five (Lipinski et al, 1995). The Rule of Five suggests that if two out of the four 
parameters are out of the given range, poor absorption or permeability is possible 
(Lipinski et al, 2001). The overall intermediate score (3/4 and 2/3) observed suggest 
that gold compounds have a good probability of oral bioavailability which is above 
the acceptable 50% bioavailability. The data obtained could be improved through 
rational design of gold compounds with LogP below five and molecular weights 
below 500g/mol. Studies have demonstrated that increases in MW results in decreased 
absorption, permeation and bioavailability (Camenisch et al., 1998; Chae et al., 2005). 
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Only three compounds exhibited a 100% Lipinski’s score (as shown in Table 3.2), 
which predicts good permeability (intestinal and blood brain barrier; Navia et al., 
1996, Testa et al., 1996) by the gold compounds on a whole.  
 
The fragments that contribute toward good oral bioavailability should be considered 
during design and development of future gold based therapeutic agents. In addition, 
sufficient understanding of structures identified to limit bioavailability can be used to 
facilitate drug design. Taken together, the compounds were clearly not well designed 
in line with theoretical predictions. As predictions are indicators of drug candidates 
these compounds were not good candidates for drug discovery. Based on theoretical 
screening, compound fragments identified to frequent good drug-likeness (AB10 and 
AB11) and good oral bioavailability (AB17, AB31 and AB38) could be used to 
rationally optimize second generation HIV-1 inhibitors. However, theoretical 
techniques used in this study cannot be used to predict whether a compound will have 
anti-HIV activity.   
 
4.2. Aqueous solubility  
 
All the gold compounds were subsequently screened for aqueous solubility to confirm 
the compounds preference to interact with polar environments containing hydrogen 
bond donors or acceptors (Kellogg et al., 2005). In concept, aqueous solubility of a 
solute is the concentration (mol/l) of its saturated aqueous solution; which is affected 
by MW and the amount of energy required to dissociate from crystalline structure into 
solution (Kellogg et al., 2005; Wang et al., 2007). In this study no correlation could 
be made between the gold compound aqueous solubility and MW (data not shown). A 
possible reason for this is that a small number of compounds were investigated.  
 
In general the gold compounds exhibited moderate solubility with 9% (n=4) of the 
gold compounds being water insoluble which suggests potential problems for in vitro 
testing, because this could lead to poor reproducibility and false positives in bioassays 
(Mondal et al., 2009; Di and Kerns, 2006). In total 27% (n=12) of gold compounds 
exhibited favourable intermolecular adhesive interactions with water molecules 
therefore resulting in aqueous solubility above 500µM. AB13 was isolated as a salt 
that contain a carboxyl moiety, therefore the good solubility it exhibited was 
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attributed to these properties which supports findings by Starr and King, 1992. They 
observed that the solubility of carboxylic acid in organic solvents increased sharply as 
water concentration in the solvents increased (Starr and King, 1992). The aqueous 
solubility of AB15 and AB19 was attributed to the imidazoles (which is known to be 
miscible in water at a concentration of 663g/L: 
http://www.inchem.org/documents/sids/sids/288324.pdf accessed 07-09-2011) that 
form part of their chemical structures. The good solubility of compounds AB31, 
AB32 and AB37 was attributed to their constituent adenine moieties previously 
reported to be soluble in pure water (Krzaczkowska et al., 2004). No correlation could 
be drawn between the predictive analysis (cLogP and LogS) and the aqueous 
solubility study. The lack of correlation between parameters was associated with the 
limited number of gold based drugs that could be used to form databases for in silico 
drug discovery programs such as the Osiris Property Explorer. The compounds from 
Series 1, Series 2, Series 3, Series 4 and Series 5 (except AB45) are classified gold(I); 
and the remaining are gold(III). Overall better aqueous solubility was observed by 
gold(I) when compared to gold(III). For instance, gold(I) compounds AB13, AB17, 
AB19, AB31, AB32, AB35-AB38 and AB40-AB44 exhibited solubility ≥400µM. 
Future design of HIV-1 inhibitors in our laboratory will consider structural fragments 
in gold compounds observed to be aqua soluble while minimizing fragments that were 
frequently found in low solubility compounds.    
 
4.3. Compound cytotoxicity in the PM1 cell line and PBMCs  
 
The cytotoxicity of gold compounds was evaluated in PM1 cell lines and PBMCs 
(Table 3.4). An overall high cytotoxicity was observed and was possibly due to the 
fact that gold compounds are known to induce increased levels of reactive oxygen 
species (ROS) (Kudrin et al., 2000) resulting in oxidative stress (Omata et al., 2006) 
through destructive interactions with cellular molecules (DNA, proteins and lipids) 
(Thannickal and Fanburg, 2000). Other reasons include gold compounds varying 
oxidation states which could lead to undesired redox properties in biological media 
(Shaw, 1999); and the associated ligands (the ethyl acetate, phenylphosphine and 
pyrazole fragments) were predicted to induce toxicity by the Osiris Property Explorer 
which was discussed in section 4.1. The gold(I) compounds were observed to be more 
cytotoxic than the gold(III), although all compounds that exhibited cytotoxicity  
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≥100µM were gold(I) (Table 3.4). Gold(III) cytoxicity was associated with the 
compounds reduction to gold(I), while gold(I) cytotoxicity was associated with ligand 
stability. The gold(I) was exposed while gold(III) was embedded within the chemical 
structure and this made the chemical structure of gold(III) more stable, because it was  
not as exposed to interactions with proteins. The compounds in Series 1 exhibited no 
cytotoxicity in PM1 cells but since these were not soluble in DMSO or aqueous 
media, the absence of cellular uptake and compound precipitation out of solution 
could explain the lack of cytotoxicity observed. The cytotoxicity of Series 2 
compounds in PBMCs and the PM1 cell line were comparable and less cytotoxic 
when compared to the control auranofin. The cytotoxicity of auranofin in PM1 cells 
observed in this study was comparable to that reported by Vergara (CC50 = 1.25 ± 
0.5/CC50 = 1.5 ± 0.5) in ovarian carcinoma cell lines sensitive (A2780/S) or resistant 
to cisplatin (A2780/R; Vergara et al., 2010). AZT exhibited minimal cytotoxicity and 
the gold compounds fared poorly in comparison. Ultimately, it is understood that 
future drug candidates need to match or improve on the cytotoxicity profiles exhibited 
by currently utilized drugs. The cytotoxicity studies will aid future drug design and 
development because chemical structures frequently associated with cytotoxicity 
would be excluded. Those fragments associated with low cytotoxicity would be 
theoretically coupled with those associated with aqueous solubility and anti-HIV-RT 
and IN inhibition to produce derivatives with highly drug like properties.  
 
4.4. Direct HIV-1 enzyme inhibition by gold compounds 
 
The compounds were initially tested for HIV-1 IN inhibition. In total 2 compounds 
exhibited inhibition greater than 50% (namely, AB39 and AB04) and another 8% 
demonstrated inhibition between 40%-50% at a single dose of 10µM (Table 3.5). A 
10µM concentration was used as a cut-off concentration because beyond this 
inhibition was likely to be associated with non-specificity of compounds. Greater 
degrees of inhibition were expected because HIV-1 integrase is known to consist of 8 
cysteine residues. The N-terminal domain of integrase has a His2Cys2 motif with two 
cysteines vital to enzyme activity. Mutations to this His2Cys2 have been reported to 
induce IN paralysis (Cai et al., 1997). The zinc binding motif within the amino-
terminal domain is also known to contain Cys moieties essential for zinc atom 
coordination (Cys40 and Cys43; Marchand et al., 2009). Other Cys residues essential 
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for integration have been identified within the catalytic core; namely Cys56, Cys65 
and Cys130 (Carayon et al., 2010). Because of the knowledge of gold compounds 
affinity for cysteine residues, and the fact that the IN enzyme consists of eight 
exposed cysteines, considerable inhibition was expected; however, this was not 
observed. Structural alterations to these compounds would include structure activity 
relationships to enhance their drug-likeness, solubility and anti-HIV-1 IN potency. 
The information obtained from the moderate HIV-1 IN inhibition by AB39 (Series 5) 
and AB04 (Series 1) would be useful for future gold based drug design of HIV-1 IN 
inhibitors. The structures can be used to design derivatives with high docking scores 
against HIV-1 IN in silico, which are likely to induce potent inhibition in vitro 
subsequent to their synthesis.   
 
All gold compounds were tested for HIV-1 RT inhibition at a concentration of 10µM 
and 82% of compounds showed a varying degree of activity as shown in Table 3.6. In 
total 24% (n=11) of the compounds (AB05-AB11, AB35 AB39, AB41, and AB42) 
tested showed good HIV-1 RT inhibition (60.26% to 77.8%). The compounds were 
further assessed for RT inhibition at concentrations 1µM, 0.5µM and 0.1µM in which 
a concentration dependent inhibition was observed. The compounds AB05-AB11 
demonstrated good anti-HIV RT activity in particular AB05, AB06, AB07 and AB08 
which exhibited nanomolar scale inhibition. Such inhibition at nanomolar 
concentration will reduce compound toxicity because it implies the use of less 
compound in vivo. This anti-HIV RT activity observed supports that of other gold 
compounds previously reported in literature (IC50 values determined ranged from 
0.31µM to 28.4µM which were comparable to those in this study; Sun et al., 2004), 
and implies that such compounds be considered in future design and development of 
HIV-1 RT inhibitors. Sun et al evaluated gold porphorins for in vitro inhibition of 
HIV-1 RT and in combination with AZT. When tested in combination with AZT, gold 
porphorins demonstrated synergistic inhibitory effects of the HIV-1 RT (Sun et al., 
2004). Assessment of structure activity relationships for compounds AB05-AB11 
could lead to the design of drug-like second generation gold based HIV RT inhibitors, 
and the current study provides a start for the development of such inhibitors. The 
relevant chemical structure for RT inhibition requires identification; then thereafter 
the information from the Osiris Property Explorer and the Lipinski’s Rule of Five 
 Chapter 4 
 80 
analyses would apply in the development of highly drug-like compounds with 
sufficient bioavailability.   
 
Since only gold(III) compounds were able to inhibit HIV-1 RT, this suggested that 
their physical structures were stable for a duration that allowed the induction of 
inhibition. To exonerate the inhibitors of their cytotoxic effects while retaining their 
anti-HIV-1 RT efficacy, these gold(III) HIV RT inhibitors could be modified to 
gold(I) while retaining their core structure. These modifications would reduce 
undesired factors such serum binding, instability and cytotoxicity.  
 
The compounds were initially tested for inhibition of a mutant HIV-1 RT that lacked 
RNaseH activity as illustrated in Figure 3.7. This inhibition was an indication that 
these gold compounds inhibit the polymerase activity of the enzyme thereby 
excluding interaction with RNaseH as a mechanism of action; due to the wide 
structural differences between the two sub-domains (Budihas et al., 2005). The gold 
compounds were further investigated against a 3TC resistant mutant HIV-1HXB2 
Reverse Transcriptase/M184V. The compounds AB05-AB11 demonstrated potent 
inhibition of this mutant enzyme (Figure 3.8). In addition, the fact that these 
compounds are not nucleotides/nucleosides analogues excluded a NRTI/NsRTI 
mechanism of action as a possibility. This information therefore suggested that second 
generation rational drug design should focus on the p66 subunit of HIV-1 RT as the 
target for gold-based compounds. The potent inhibition of HIV-1 RT by AB05, 
AB06, AB07 and AB08 inspired further investigations into their mechanism of action. 
Gold compounds are known to undergo ligand exchange with cysteine-rich peptides 
on protein surfaces (Shaw, 1989). Since two cysteinyl residues (C38 and C280) are 
exposed on the HIV-1 RT surface (Ratner et al., 1985), interaction with these would 
likely contribute to the inhibition observed. The mechanism of action could be 
through active site binding and/or binding of the C38 and C280 essential for RT’s 
catalytic function or both. Compound AB39 showed moderate RT and integrase 
inhibition therefore it would be necessary to exclude possible non-specific inhibition 
by testing the compounds for anti-RNaseH activity since this RT subdomain is closely 
related to integrase in structure (Marchand et al., 2008).  
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4.5. Gold compound HIV-1 inhibition in PBMC’s 
 
Subsequent to direct HIV-1 RT inhibition of the compounds AB05-AB11, the 
compounds were submitted to the NIH (USA) for evaluation of antiviral inhibition in 
PBMCs. PBMCs were used because they are the major target cells of HIV-1, and 
express the CD4 receptor, which is the major receptor for primary HIV-1 isolates 
(Sattentau and Weiss, 1988), as well as the CCR5 and CXCR4 co-receptors (Bleul et 
al., 1997). The inhibition observed in direct RT assays was not observed against the 
macrophage-tropic HIV-1Ba-L and T-cell tropic HIV-1NL4 viral isolates in PBMCs 
(Chekmasova and Strayer, 2006; Abstract), as illustrated in Table 3.8. The HIV-1Ba-L 
and HIV-1NL4 respectively utilizes the CCR5 and the CXCR4 receptors which are the 
principal co-receptors for HIV-1 infection. HIV-1 entry is therefore an exceptional 
therapeutic target, but the lack of inhibition of either viral isolate observed in this 
study tentatively excludes tropism associated inhibition by gold compounds as a 
possibility. The compounds were observed to exhibit HIV-1 RT inhibition at 
nanomolar concentrations in cell free assays as discussed in section 4.4. As 
micromolar concentrations were utilized in the PBMCs for antiviral assay, inhibition 
was expected even if not equivalent to that in direct assays but none was observed. 
The altered cell based inhibition was attributed to several reasons i.e. serum protein 
binding, bioavailability and cytotoxicity. Compound cytotoxicity was associated with 
the absence of viral proliferation, meaning the IC50 values observed were an 
indication of cell death therefore the virus could not replicate. This was indicated 
through cytotoxicity curves that paralleled the antiviral curves. Other factors that 
could have prohibited antiviral inhibition in PBMCs include serum protein binding 
which was shown to alter bioavailability of inhibitor to the target (refer to Figure 3.9). 
Thus, the second generation compounds AB05-AB11 should be rationally designed 
for optimal binding affinity against the desired target (HIV-1 RT) while minimizing 
their affinity for unwanted targets such as serum proteins. A targeted drug delivery 
system could be considered during development of gold based drug design; or the 
compounds should be designed such that the gold component is protected to reduce 
binding with serum proteins. Reduced serum binding would add to compound 
stability and reduced cytotoxicity due to compound breakdown. 
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4.6. Effect of serum proteins on direct HIV-1 RT inhibition by gold compounds  
 
Serum protein binding was assessed as a possible parameter that led to loss of 
antiviral efficacy in PBMCs. To assess serum protein binding, the direct HIV-1 RT 
assay was modified to contain 10% foetal bovine serum and compound efficacy was 
observed to have reduced considerably for all four compounds (AB05, AB06, AB07 
and AB08) tested. Albumin is the predominant extracellular protein in blood and has 
been reported to bind gold compounds. For this reason, the effect of HSA was 
evaluated separately using 4.5mg/ml HSA which is the typical concentration in HIV-1 
infected individuals (Corbett et al., 1999). The addition of HSA into the assay also 
introduced considerable fold-change reductions in anti-HIV-1 RT efficacy. Protein-
drug interactions are known to present widespread ADMET implications such as the 
reduced/loss of direct inhibition observed (Pavey et al., 2001; Kratochwil et al., 
2002).  
 
The loss of potency in PBMCs (anti-HIV assay) may thus be attributed to the 
presence of serum proteins in the culture media, which binds most of the compound 
leaving a minimal free fraction which cannot elicit a considerable pharmacological 
response (reviewed in Gleeson, 2008). Serum protein binding of drugs has previously 
been correlated to MW of drug agents, where increased MW led to increased plasma 
protein binding (Abraham, 1993; reviewed in Gleeson, 2008). Approximately 87% of 
the gold compounds tested have molecular weights greater than 500g/mol. Therefore, 
the high MW and the Cys residues from serum proteins enhanced the probability of 
blood plasma binding. These proteins (HSA)-drug (AB05-AB11) binding studies 
were assessed using STD NMR techniques and a level of interaction was observed. 
AB07 and AB09 were an exception since no STD signal was observed, which either 
indicates high affinity binding or lack of binding. A strong STD NMR signal confirms 
binding of compound to protein while the lack of an STD NMR signal is consistent 
with the notion that compound is solvent-exposed and is not in close proximity with 
the protein surface (Haselhorst et al., 2006).  
 
AB05 was used as a representative compound in competitive binding studies in which 
the mechanism of albumin binding was evaluated. The compound was used with the 
aim of defining the meaning of the slightly visible STD NMR, as either high affinity 
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binding or lack of binding. AB05 was observed to displace auranofin which has been 
known to bind Cys34 (Shaw, 1999) on the surface of HSA, which implicates a 
common binding site for the gold-based compounds. Since Auranofin is known as a 
high affinity binder to HSA, its displacement indicates that gold compounds are likely 
to bind Cys34 with comparable affinity.  
 
Serum binding and its effect were further evaluated through compound stability 
studies in media containing 10% FCS. The gold compounds were observed to 
metabolize in 10% complete culture media. This was observed from the gradual 
changes in STD spectra. A diminishing STD signal was observed for AB05, AB06 
and AB08 at approximately 9.2ppm’s, 1.4ppm’s and 1.41ppm’s respectively. The 
metabolisation was shown to be immediate after the addition of compound into media, 
since changes were observed in the first thirty minutes and continued until compounds 
were completely metabolized after twenty-four (AB05) to seventy-two hours (AB06 
and AB08).  AB07 was observed to exhibit an increase in STD spectral intensity at 
9.5ppm’s which implicated gold metabolite formation. The metabolite formed was 
shown to interact with serum proteins in culture media as described in section 4.6. 
The fact that such compounds interact with serum proteins and subsequently their 
anti-HIV-1 RT efficacy is reduced, excludes them from classification as pro-drugs. 
 
4.7. Summary  
 
Due to the severity of the HIV-1 pandemic and the development of antiretroviral drug 
resistance to currently approved FDA drugs, it is essential to continue with the 
development of novel anti-HIV drugs with improved clinical and pharmacological 
profiles. Thus the aim of this study was to analyse 45 available gold based drugs with 
the intention of obtaining data that could be used when designing second generation 
gold-based inhibitors of HIV-1 replication. The gold-based compounds were assessed 
for the following parameters: theoretical drug-likeness, aqueous solubility, 
cytotoxicity, serum binding, cell based inhibition and direct enzymatic activity.  The 
Osiris Property Explorer predicted low drug-likeness scores and drug scores for all 
gold compounds. The Lipinski’s Rule of Five predicted an overall intermediate oral 
bioavailability for gold compounds with an exception of a few which exhibited high 
scores. The theoretical data obtained could not be used to filter gold compounds 
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because conclusions on HIV-1 inhibition could not be drawn from them. Compounds 
were grouped according to similarities in chemical structure therefore a correlation 
existed between each group and the biological properties such as the hydrophilicity of 
the group AB01-AB04, the high cytotoxicity within the group AB14-AB38 and direct 
inhibition of HIV-1 RT within the group of compounds (AB05-AB11); which was 
diminished in PBMC inhibition assay studies. Gold compounds were observed to 
undergo chemical changes through STD NMR due to metal centre reduction during 
interaction with serum proteins. Serum proteins were also observed to have an 
antagonistic effect on the anti-HIV-1 potency of the gold compounds, and as a result 
reduced anti-HIV-1 RT activity was observed in the PBMC assay. Gold compounds 
were shown to inhibit the polymerase activity of HIV-1 RT while strand transfer was 
implicated a possible mechanism of action for integrase inhibition. The test 
compounds were not rationally designed, but inhibition of HIV-1 RT and IN by gold 
(III) compounds provides an opportunity for rational design of second generation 
inhibitors with improved biological profiles.   
 
4.8. Concluding remarks  
 
The findings of this study demonstrated the value of predictive screening coupled 
with experimental analysis of synthetic compounds. The theoretical techniques 
predicted low drug scores for the gold-based compounds but predicted good drug-
likeness and drug scores for Raltegravir. The low theoretical drug scores were 
validated in vitro by undesired cytotoxicity, solubility and protein binding studies 
although compounds within Series 2 exhibited good HIV-1 RT inhibition. Inhibition 
of HIV-1 alone proved not to equal good drug-likeness as other biological properties 
are equally important for predicting drug-likeness like with Raltegravir. In conclusion, 
sufficient data was generated to considerably aid the rational design of anti-HIV-1 
gold-based compounds. Since compounds within Series 2 were structurally related, 
tailoring of second generation inhibitors using their core chemical structure for 
improved biological properties and HIV-1 RT inhibition is possible. 
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4.9. Future Prospects 
 
Gold compounds AB05, AB06, AB07 and AB08 have demonstrated potential as HIV-
1 inhibitors therefore are classified as drug discovery HITS. Further studies are 
required to fully develop these HIT compounds into more effective LEAD candidates. 
Other compounds that were promising drug discovery HIT candidates included AB09, 
AB10 and AB11 suitable for anti HIV-RT activity. Furthermore, AB04 was a 
promising inhibitor of HIV-1 IN while AB39 was a promising candidate for dual 
inhibitors of HIV-1 RT and HIV-1 IN.  
 
For future work the following is recommended:  
• Rational design of compounds AB05-AB11 derivatives with high 
docking/drug-likeness scores and the evaluation of adherence to the Lipinski’s 
Rule of Five.  
• Evaluation of AB39 and AB10 as possible HIV-1 RT RNaseH inhibitors.  
• Rational design of AB39 and AB10 compound derivatives with high docking 
against HIV-1 integrase and high drug scores.  
• Chemical synthesis of theoretically successful derivatives of AB05-AB11.  
• Evaluation of direct and cell based HIV-1 RT inhibition and ADMET 
properties.  
• In depth assessment of the anti-HIV RT mechanism of action by the gold 
based compound derivatives of AB05-AB11.  
• Development of a targeted drug delivery system to reduce serum binding of 
compounds and increase efficiency of uptake into infected cells. 
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